

The Future of 2023 ICD-10-CM/PCS has Arrived:

Insight into the 2023 ICD-10 Code Sets



Disclaimer Statement

This presentation was current at the time it was published or provided via the web and is designed to provide accurate and authoritative information in regard to the subject matter covered. The information provided is only intended to be a general overview with the understanding that neither the presenter nor the event sponsor is engaged in rendering specific coding advice. It is not intended to take the place of either the written policies or regulations. We encourage participants to review the specific regulations and other interpretive materials as necessary.

All CPT® codes are trademarked by the American Medical Association (AMA) and all revenue codes are copyrighted by the American Hospital Association (AHA).

Agenda

- CM chapter specific code additions, deletions, and revisions
- CM guideline changes
- PCS chapter specific code additions, deletions, and revisions
- PCS guideline changes
- MS-DRG Updates



CM Code Changes:

Additions, Deletions, and Revisions by Chapter

CM Code Changes Summary

For 2023 Overall Changes to CM:

- 1,176 new codes
- 28 revisions
- 287 deletions
- Total CM codes from 72,750 to 73,639
- 602 new POA Exempt codes added
- MCC/CC Changes:
 - 35 new MCCs
 - 5 deleted MCCs
 - 136 new CCs
 - 12 deleted CC



Diagnosis	TABLE 61.1 - ADDITIONS TO THE MCC Description		
D59.30	Hemolytic-uremic syndrome, unspecified		
	Infection-associated hemolytic-uremic syndrome		
059.32	Hereditary hemolytic-uremic syndrome		
059.39	Other hemolytic-uremic syndrome		
71.010	Dissection of ascending aorta		
	Dissection of aortic arch		ABLE 61.2 - DELETIONS TO THE MCC LIST
	Dissection of descending thoracic aorta		
	Dissection of thoracic aorta, unspecified	Diagnosis	
	Thoracic aortic aneurysm, ruptured, unspecified	Code	Description
71.11	Aneurysm of the ascending aorta, ruptured	D59.3	Hemolytic-uremic syndrome
71.12	Aneurysm of the aortic arch, ruptured	171.01	Dissection of thoracic aorta
	Aneurysm of the descending thoracic aorta, ruptured	171.1	Thoracic aortic aneurysm, ruptured
71.30	Abdominal aortic aneurysm, ruptured, unspecified	171.3	Abdominal aortic aneurysm, ruptured
71.31	Pararenal abdominal aortic aneurysm, ruptured		· · · · · · · · · · · · · · · · · · ·
71.32	Juxtarenal abdominal aortic aneurysm, ruptured	I71.5	Thoracoabdominal aortic aneurysm, ruptured
71.33	Infrarenal abdominal aortic aneurysm, ruptured		
71.50	Thoracoabdominal aortic aneurysm, ruptured, unspecified		
71.51	Supraceliac aneurysm of the abdominal aorta, ruptured		
71.52	Paravisceral aneurysm of the abdominal aorta, ruptured		
√196.A4	Flail chest associated with chest compression and cardiopulmonary resuscitation		
06.1XAA	Traumatic cerebral edema with loss of consciousness status unknown, initial encounter		
06.31AA	Contusion and laceration of right cerebrum with loss of consciousness status unknown, initial encounter		
06.32AA	Contusion and laceration of left cerebrum with loss of consciousness status unknown, initial encounter		
606.33AA	Contusion and laceration of cerebrum, unspecified, with loss of consciousness status unknown, initial encou	nter	
606.34AA	Traumatic hemorrhage of right cerebrum with loss of consciousness status unknown, initial encounter		
06.35AA	Traumatic hemorrhage of left cerebrum with loss of consciousness status unknown, initial encounter		
606.36AA	Traumatic hemorrhage of cerebrum, unspecified, with loss of consciousness status unknown, initial encounter	er	
606.37AA	Contusion, laceration, and hemorrhage of cerebellum with loss of consciousness status unknown, initial enco	ounter	
06.38AA	Contusion, laceration, and hemorrhage of brainstem with loss of consciousness status unknown, initial encountries of consciousness of	unter	
06.4XAA	Epidural hemorrhage with loss of consciousness status unknown, initial encounter		
	Traumatic subdural hemorrhage with loss of consciousness status unknown, initial encounter		
	Traumatic subarachnoid hemorrhage with loss of consciousness status unknown, initial encounter		
	Primary blast injury of brain, not elsewhere classified with loss of consciousness greater than 24 hours witho		
	Primary blast injury of brain, not elsewhere classified with loss of consciousness of any duration with death of		
606.8A8A	Primary blast injury of brain, not elsewhere classified with loss of consciousness of any duration with death of	due to other ca	use prior to regaining consciousness, initial encounter

	TABLE 6J.1 - ADDITIONS TO THE CC LIST
Diagnosis	Description
D68.00	Von Willebrand disease, unspecified
D68.01	Von Willebrand disease, type 1
D68.020	Von Willebrand disease, type 2A
D68.021	Von Willebrand disease, type 2B
D68.022	Von Willebrand disease, type 2M
D68.023	Von Willebrand disease, type 2N
D68.029	Von Willebrand disease, type 2, unspecified
D68.03	Von Willebrand disease, type 3
D68.04	Acquired von Willebrand disease
D68.09	Other von Willebrand disease
D81.82	Activated Phosphoinositide 3-kinase Delta Syndrome [APDS]
E87.20	Acidosis, unspecified
E87.21	Acute metabolic acidosis
E87.22	Chronic metabolic acidosis
E87.29	Other acidosis
F01.511	Vascular dementia, unspecified severity, with agitation
F01.518	Vascular dementia, unspecified severity, with other behavioral disturbance
F01.52	Vascular dementia, unspecified severity, with psychotic disturbance
F01.53	Vascular dementia, unspecified severity, with mood disturbance
F01.54	Vascular dementia, unspecified severity, with anxiety
F01.A11	Vascular dementia, mild, with agitation
F01.A18	Vascular dementia, mild, with other behavioral disturbance
F01.A2	Vascular dementia, mild, with psychotic disturbance
F01.A3	Vascular dementia, mild, with mood disturbance
F01.A4	Vascular dementia, mild, with anxiety
F01.B11	Vascular dementia, moderate, with agitation
F01.B18	Vascular dementia, moderate, with other behavioral disturbance
F01.B2	Vascular dementia, moderate, with psychotic disturbance
F01.B3	Vascular dementia, moderate, with mood disturbance
F01.B4	Vascular dementia, moderate, with anxiety
F01.C11	Vascular dementia, severe, with agitation
F01.C18	Vascular dementia, severe, with other behavioral disturbance
F01.C2	Vascular dementia, severe, with psychotic disturbance
F01.C3	Vascular dementia, severe, with mood disturbance
F01.C4	Vascular dementia, severe, with anxiety
	Confidential Denot distribute @Converight \(\frac{1}{12}\) to be one of

TABLE 6J.1 - ADDITIONS TO THE CC LIST

	is Code Description
F02.811	Dementia in other diseases classified elsewhere, unspecified severity, with agitation
F02.818	Dementia in other diseases classified elsewhere, unspecified severity, with other behavioral disturbance
F02.82	Dementia in other diseases classified elsewhere, unspecified severity, with psychotic disturbance
F02.83	Dementia in other diseases classified elsewhere, unspecified severity, with mood disturbance
F02.84	Dementia in other diseases classified elsewhere, unspecified severity, with anxiety
F02.A11	Dementia in other diseases classified elsewhere, mild, with agitation
F02.A18	Dementia in other diseases classified elsewhere, mild, with other behavioral disturbance
F02.A2	Dementia in other diseases classified elsewhere, mild, with psychotic disturbance
F02.A3	Dementia in other diseases classified elsewhere, mild, with mood disturbance
F02.A4	Dementia in other diseases classified elsewhere, mild, with anxiety
F02.B11	Dementia in other diseases classified elsewhere, moderate, with agitation
F02.B18	Dementia in other diseases classified elsewhere, moderate, with other behavioral disturbance
F02.B2	Dementia in other diseases classified elsewhere, moderate, with psychotic disturbance
F02.B3	Dementia in other diseases classified elsewhere, moderate, with mood disturbance
F02.B4	Dementia in other diseases classified elsewhere, moderate, with anxiety
F02.C11	Dementia in other diseases classified elsewhere, severe, with agitation
F02.C18	Dementia in other diseases classified elsewhere, severe, with other behavioral disturbance
F02.C2	Dementia in other diseases classified elsewhere, severe, with psychotic disturbance
F02.C3	Dementia in other diseases classified elsewhere, severe, with mood disturbance
F02.C4	Dementia in other diseases classified elsewhere, severe, with anxiety
F03.911	Unspecified dementia, unspecified severity, with agitation
F03.918	Unspecified dementia, unspecified severity, with other behavioral disturbance
F03.92	Unspecified dementia, unspecified severity, with psychotic disturbance
F03.93	Unspecified dementia, unspecified severity, with mood disturbance
F03.94	Unspecified dementia, unspecified severity, with anxiety
F03.A11	Unspecified dementia, mild, with agitation
F03.A18	Unspecified dementia, mild, with other behavioral disturbance
F03.A2	Unspecified dementia, mild, with psychotic disturbance
F03.A3	Unspecified dementia, mild, with mood disturbance
F03.A4	Unspecified dementia, mild, with anxiety
F03.B11	Unspecified dementia, moderate, with agitation
F03.B18	Unspecified dementia, moderate, with other behavioral disturbance
F03.B2	Unspecified dementia, moderate, with psychotic disturbance
F03.B3	Unspecified dementia, moderate, with mood disturbance
F03.B4	Unspecified dementia, moderate, with anxiety
F03.C11	Unspecified dementia, severe, with agitation
F03.C18	Unspecified dementia, severe, with other behavioral disturbance
	Confidential • Do not distribute • ©Copyright Vitalware, LLC. All rights reserved.

	TABLE 6J.1 - ADDITIONS TO THE CC LIST
Diagnosis	Description
F02.C2	Dementia in other diseases classified elsewhere, severe, with psychotic disturbance
F02.C3	Dementia in other diseases classified elsewhere, severe, with mood disturbance
F02.C4	Dementia in other diseases classified elsewhere, severe, with anxiety
F03.911	Unspecified dementia, unspecified severity, with agitation
F03.918	Unspecified dementia, unspecified severity, with other behavioral disturbance
F03.92	Unspecified dementia, unspecified severity, with psychotic disturbance
F03.93	Unspecified dementia, unspecified severity, with mood disturbance
F03.94	Unspecified dementia, unspecified severity, with anxiety
F03.A11	Unspecified dementia, mild, with agitation
F03.A18	Unspecified dementia, mild, with other behavioral disturbance
F03.A2	Unspecified dementia, mild, with psychotic disturbance
F03.A3	Unspecified dementia, mild, with mood disturbance
F03.A4	Unspecified dementia, mild, with anxiety
F03.B11	Unspecified dementia, moderate, with agitation
F03.B18	Unspecified dementia, moderate, with other behavioral disturbance
F03.B2	Unspecified dementia, moderate, with psychotic disturbance
F03.B3	Unspecified dementia, moderate, with mood disturbance
F03.B4	Unspecified dementia, moderate, with anxiety
F03.C11	Unspecified dementia, severe, with agitation
F03.C18	Unspecified dementia, severe, with other behavioral disturbance
F03.C2	Unspecified dementia, severe, with psychotic disturbance
F03.C3	Unspecified dementia, severe, with mood disturbance
F03.C4	Unspecified dementia, severe, with anxiety
F06.71	Mild neurocognitive disorder due to known physiological condition with behavioral disturbance
120.2	Refractory angina pectoris
125.112	Atherosclerosic heart disease of native coronary artery with refractory angina pectoris
125.702	Atherosclerosis of coronary artery bypass graft(s), unspecified, with refractory angina pectoris
125.712	Atherosclerosis of autologous vein coronary artery bypass graft(s) with refractory angina pectoris
125.722	Atherosclerosis of autologous artery coronary artery bypass graft(s) with refractory angina pectoris
125.732	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with refractory angina pectoris
125.752	Atherosclerosis of native coronary artery of transplanted heart with refractory angina pectoris
125.762	Atherosclerosis of bypass graft of coronary artery of transplanted heart with refractory angina pectoris
125.792	Atherosclerosis of other coronary artery bypass graft(s) with refractory angina pectoris
131.31	Malignant pericardial effusion in diseases classified elsewhere
131.39	Other pericardial effusion (noninflammatory)
147.20	Ventricular tachycardia, unspecified
147.21	Torsades de pointes Confidential - Do not distribute - ©Copyright Vitalware, LLC. All rights reserved.

TABLE CLA. ADDITIONS TO THE COLIST

	TABL	E 6J.1 - ADDIT	IONS TO THE CC LIST
Diagnos	s Description		
147.29	Other ventricular tachycardia		
J95.87	Transfusion-associated dyspnea (TAD)		
M96.A1	Fracture of sternum associated with chest compression and cardio	pulmonary re	esuscitation
/196.A2	Fracture of one rib associated with chest compression and cardiop	ulmonary res	suscitation
/196.A3	Multiple fractures of ribs associated with chest compression and o	ardiopulmon	ary resuscitation
M96.A9	Other fracture associated with chest compression and cardiopulm	onary resusci	tation
P28.30	Primary sleep apnea of newborn, unspecified		
P28.31	Primary central sleep apnea of newborn		
P28.32	Primary obstructive sleep apnea of newborn		TABLE 6J.1 - ADDITIONS TO THE CC LIST
P28.33	Primary mixed sleep apnea of newborn	Diagram	
28.39	Other primary sleep apnea of newborn	Diagnos	
28.40	Unspecified apnea of newborn	Code	Description
28.41	Central neonatal apnea of newborn	Q21.19	Other specified atrial septal defect
28.42	Obstructive apnea of newborn	Q21.20	Atrioventricular septal defect, unspecified as to partial or complete
28.43	Mixed neonatal apnea of newborn	Q21.21 Q21.22	Partial atrioventricular septal defect Transitional atrioventricular septal defect
28.49	Other apnea of newborn	Q21.22 Q21.23	Complete atrioventricular septal defect
221.10	Atrial septal defect, unspecified	Q85.81	PTEN tumor syndrome
Q21.11	Secundum atrial septal defect	Q85.82	Other Cowden syndrome
Q21.12	Patent foramen ovale	Q85.83	Von Hippel-Lindau syndrome
Q21.13	Coronary sinus atrial septal defect	Q85.89	Other phakomatoses, not elsewhere classified
Q21.14	Superior sinus venosus atrial septal defect		A Concussion with loss of consciousness status unknown, initial encounter
Q21.15	Inferior sinus venosus atrial septal defect		A Diffuse traumatic brain injury with loss of consciousness status unknown, initial encounter
Q21.16	Sinus venosus atrial septal defect, unspecified		A Unspecified focal traumatic brain injury with loss of consciousness status unknown, initial encounter
			Injury of right internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness status unknown, initial encounter
			A Injury of left internal carotid artery, intracranial portion, not elsewhere classified with loss of consciousness status unknown, initial encounter
			A Other specified intracranial injury with loss of consciousness status unknown, initial encounter A Primary blast injury of brain, not elsewhere classified without loss of consciousness, initial encounter
			A Primary blast injury of brain, not elsewhere classified with loss of consciousness of 30 minutes or less, initial encounter
			A Primary blast injury of brain, not elsewhere classified with loss of consciousness of 31 minutes to 59 minutes, initial encounter
			A Primary blast injury of brain, not elsewhere classified with loss of consciousness of 1 hour to 5 hours 59 minutes, initial encounter
			Primary blast injury of brain, not elsewhere classified with loss of consciousness of 6 hours to 24 hours, initial encounter

S06.9XAA Unspecified intracranial injury with loss of consciousness status unknown, initial encounter Confidential • Do not distribute • ©Copyright Vitalware, LLC. All rights reserved.

S06.8A9A Primary blast injury of brain, not elsewhere classified with loss of consciousness of unspecified duration, initial encounter S06.8AAA Primary blast injury of brain, not elsewhere classified with loss of consciousness status unknown, initial encounter

S06.8A5A Primary blast injury of brain, not elsewhere classified with loss of consciousness greater than 24 hours with return to pre-existing conscious level, initial encounter

	TABLE 6J.2 - DELETIONS TO THE CC LIST
Diagnosis	s Description
D68.0	Von Willebrand's disease
E87.2	Acidosis
F01.51	Vascular dementia with behavioral disturbance
F02.81	Dementia in other diseases classified elsewhere with behavioral disturbance
F03.91	Unspecified dementia with behavioral disturbance
131.3	Pericardial effusion (noninflammatory)
147.2	Ventricular tachycardia
P28.3	Primary sleep apnea of newborn
P28.4	Other apnea of newborn
Q21.1	Atrial septal defect
Q21.2	Atrioventricular septal defect
Q85.8	Other phakomatoses, not elsewhere classified

Chapter 1- Certain infectious and parasitic diseases (A00-B99)

Additions

B37.31 Acute candidiasis (which includes NOS)

B37.32 Chronic candidiasis (which includes recurrent vulvovaginitis, or RVVC)

Deletion

B37.3 Candidiasis of vulva and vagina

Chapter 2- Neoplasms (C00-D49)

Minor revisions- "not classified" to "not elsewhere classified"

Chapter 3- Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism (D50-D89)

Additions

D59.30 Hemolytic-uremic syndrome, unspecified MCC

D59.31 Infection-associated hemolytic-uremic syndrome MCC

D58.32 Hereditary hemolytic-uremic syndrome MCC

D59.39 Other hemolytic-uremic syndrome MCC

Deletion

D59.3 Hemolyticuremic syndrome

D68.00 Von Willebrand Disease, unspecified CC

D68.01 Von Willebrand Disease, Type I (includes partial quantitative deficiency of Von Willebrand (VW) factor and Type 1C. CC

D68.020 Von Willebrand disease, type 2A CC

D68.021 Von Willebrand disease, type 2B CC

D68.022 Von Willebrand disease, type 2M CC

D68.023 Von Willebrand disease, type 2N CC

D68.029 Von Willebrand disease, unspecified CC

<u>Deletion</u>

D68.0 Von Willebrand's disease

Chapter 3- Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism (D50-D89)

Additions

D68.03 Von Willebrand disease, type 3 CC

D68.04 Acquired Von Willebrand disease CC

D68.09 Other Von Willebrand disease CC

*Code also, if applicable, qualitative platelet defects (D69.1)

D75.821 Non-immune heparin-induced thrombocytopenia


D75.822 Immune-mediated heparin-induced thrombocytopenia

D75.828 Other heparin-induced thrombocytopenia syndrome

D75.829 Heparin-induced thrombocytopenia, unspecified

*Use additional code, if applicable, for adverse effect of heparin (T45.515-)

D81.82 Activated Phosphoinositide 3-kinase Delta Syndrome [APDS] CC



Deletion

D75.82 Heparin induced thrombocytopenia (HIT)

Chapter 4- Endocrine, nutritional and metabolic diseases (E00-E89)

Additions

E34.30 Short stature due to endocrine disorder, unspecified

E34.31 Constitutional short stature

E34.321 Primary insulin-like growth factor-1 (IGF-1) deficiency

E34.322 Insulin-like growth factor-1 (IGF-1) resistance

E34.328 Other genetic causes of short stature

E34.329 Unspecified genetic causes of short stature

E34.39 Other short stature due to endocrine disorder

E87.20 Acidosis, unspecified CC

E87.21 Acute metabolic acidosis CC

E87.22 Chronic metabolic acidosis CC

Code first underlying etiology, if applicable

E89.29 Other acidosis CC

Respiratory acidosis NOS

Deletion

E34.3 Short stature due to endocrine disorder

Deletion

E87.2 Acidosis

Deletion

Category F01 Vascular Dementia		F01.51 Vascular dementia with behavioral disturbance
F01.511	Vascular dementia, unspecified severity, with agitation CC	
F01.518	Vascular dementia, unspecified severity, with other behavioral disturbance (CC
F01.52	Vascular dementia, unspecified severity, with psychotic disturbance CC	
F01.53	Vascular dementia, unspecified severity, with mood disturbance CC	
F01.54	Vascular dementia, unspecified severity, with anxiety CC	
F01.A0	Vascular dementia, mild, without behavioral disturbance, psychotic disturba	ance, mood
	disturbance, and anxiety CC	
F01.A11	Vascular dementia, mild, with agitation CC	
F01.A18	Vascular dementia, mild, with other behavioral disturbance CC	
F01.A2	Vascular dementia, mild, with psychotic disturbance CC	
F01.A3	Vascular dementia, mild, with mood disturbance CC	
F01.A4	Vascular dementia, mild, with anxiety CC	

Additions

Additions

- F01.B0 Vascular dementia, moderate, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety CC
- F01.B11 Vascular dementia, moderate, with agitation CC
- F01.B18 Vascular dementia, moderate, with other behavioral disturbance CC
- F01.B2 Vascular dementia, moderate, with psychotic disturbance CC
- F01.B3 Vascular dementia, moderate, with mood disturbance CC
- F01.B4 Vascular dementia, moderate, with anxiety CC
- F01.C0 Vascular dementia, severe, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety CC
- F01.C11 Vascular dementia, severe, with agitation CC
- F01.C18 Vascular dementia, severe, with other behavioral disturbance CC
- F01.C2 Vascular dementia, severe, with psychotic disturbance CC
- F01.C3 Vascular dementia, severe, with mood disturbance CC
- F01.C4 Vascular dementia, severe, with anxiety CC

Deletion

•	st of other diseases found in the Code first note in at category F02)	F02.81 Dementia in other diseases classified elsewhere with behavioral disturbance
F02.811	Dementia in other diseases classified elsewhere, unspecified severity,	with agitation CC
F02.818	Dementia in other diseases classified elsewhere, unspecified severity, disturbance CC	with other behavioral
F02.82	Dementia in other diseases classified elsewhere, unspecified severity,	with psychotic disturbance CC
F02.83	Dementia in other diseases classified elsewhere, unspecified severity,	with mood disturbance CC
F02.84	Dementia in other diseases classified elsewhere, unspecified severity,	with anxiety CC
F02.A0	Dementia in other diseases classified elsewhere, mild, without behavio	ral disturbance, psychotic
	disturbance, mood disturbance, and anxiety CC	
F02.A11	Dementia in other diseases classified elsewhere, mild, with agitation Co	C
F02.A18	Dementia in other diseases classified elsewhere, mild, with other behave	vioral disturbance CC
F02.A2	Dementia in other diseases classified elsewhere, mild, with psychotic d	listurbance CC
F02.A3	Dementia in other diseases classified elsewhere, mild, with mood distu	rbance CC
F02.A4	Dementia in other diseases classified elsewhere, mild, with anxiety CC	

Additions

Category F02 Dementia in other diseases classified elsewhere

Additions

Addition	<u>S</u>			
Category F03 Unspecified Dementia (includes <i>major</i> neurocognitive disorder)				
F03.911	1 Unspecified dementia, unspecified severity, with agitation CC			
F03.918	8 Unspecified dementia, unspecified severity, with other behavioral disturbance CC			
F03.92	Unspecified dementia, unspecified severity, with psychotic disturbance	CC		
F03.93	Unspecified dementia, unspecified severity, with mood disturbance CC			
F03.94	Unspecified dementia, unspecified severity, with anxiety CC			
F03.A0	Unspecified dementia, mild, without behavioral disturbance, psychotic and anxiety CC	disturbance, mood disturbance,		
F03.A11	Unspecified dementia, mild, with agitation CC			
F03.A18	Unspecified dementia, mild, with other behavioral disturbance CC			
F03.A2	Unspecified dementia, mild, with psychotic disturbance CC	<u>Deletion</u>		
F03.A3	Unspecified dementia, mild, with mood disturbance CC	F03.91 Unspecified dementia with		
F03.A4	Unspecified dementia, mild, with anxiety CC	behavioral disturbance		


Additions

F03.B0 Unspecified dementia, moderate, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety CC F03.B11 Unspecified dementia, moderate, with agitation CC F03.B18 Unspecified dementia, moderate, with other behavioral disturbance CC Unspecified dementia, moderate, with psychotic disturbance CC F03.B3 Unspecified dementia, moderate, with mood disturbance CC F03.B4 Unspecified dementia, moderate, with anxiety CC F03.C0 Unspecified dementia, severe, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety CC F03.C11 Unspecified dementia, severe, with agitation CC F03.C18 Unspecified dementia, severe, with other behavioral disturbance CC F03.C2 Unspecified dementia, severe, with psychotic disturbance CC F03.C3 Unspecified dementia, severe, with mood disturbance CC F03.C4 Unspecified dementia, severe, with anxiety CC

Additions

F06.70 Mild neurocognitive disorder due to known physiological condition without behavioral disturbance

F06.71 Mild neurocognitive disorder due to known physiological condition with behavioral disturbance CC



Additions

F10.90 Alcohol use, unspecified, uncomplicated F10.91 Alcohol use, unspecified, in remission F11.91 Opioid use, unspecified, in remission F12.91 Cannabis use, unspecified, in remission F13.91 Sedative, hypnotic or anxiolytic use, unspecified, in remission F14.91 Cocaine use, unspecified, in remission F15.91 Other stimulant use, unspecified, in remission F16.91 Hallucinogen use, unspecified, in remission F18.91 Inhalant use, unspecified, in remission F19.91 Other psychoactive substance use, unspecified, in remission

Additions

F43.81 Prolonged grief disorder

F43.89 Other reactions to severe stress

Deletion

F43.8 Other reactions to severe stress

Revisions

Revise from: F01.50 Vascular dementia without behavioral disturbance

Revise to: F01.50 Vascular dementia, unspecified severity, without

behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety

F02.80 Dementia in other diseases classified elsewhere without behavioral Revise from:

disturbance

Revise to: F02.80 Dementia in other diseases classified elsewhere, unspecified severity, without behavioral disturbance, psychotic disturbance, mood disturbance, and

anxietv

Revise from: F03.90 Unspecified dementia without behavioral disturbance

F03.90 Unspecified dementia, unspecified severity, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety Revise to:

Chapter 6- Diseases of the Nervous System (G00-G99)

Additions

Limb Girdle Muscular Dystrophy Due to Genetic Causes:

G71.031 Autosomal dominant limb girdle muscular dystrophy

G71.032 Autosomal recessive limb girdle muscular dystrophy due to calpain-3 dysfunction

G71.033 Limb girdle muscular dystrophy due to dysferlin dysfunction

Limb Girdle Muscular Dystrophy Due to Specific Gene Mutation Causes, including Sarcoglycan Dysfunction:

G71.0340 Limb girdle muscular dystrophy due to sarcoglycan dysfunction, unspecified

G71.0341 Limb girdle muscular dystrophy due to alpha sarcoglycan dysfunction

G71.0342 Limb girdle muscular dystrophy due to beta sarcoglycan dysfunction

G71.0349 Limb girdle muscular dystrophy due to other sarcoglycan dysfunction

Chapter 6- Diseases of the Nervous System (G00-G99)

Limb Girdle Muscular Dystrophy Due to Other Gene Dysfunctions:

G71.035 Limb girdle muscular dystrophy due to anoctamin-5 dysfunction

G71.038 Other limb girdle muscular dystrophy

G71.039 Limb girdle muscular dystrophy, unspecified

Chapter 6- Diseases of the nervous system (G00-G99)

Additions

G90.A Postural orthostatic tachycardia syndrome [POTS]

G93.31 Postviral fatigue syndrome

G93.32 Myalgic encephalomyelitis/chronic fatigue syndrome

G93.39 Other post infection and related fatigue syndromes

Deletion

G93.3 Postviral fatigue syndrome

Chapter 6- Diseases of the nervous system (G00-G99)

Revisions

Revise from: G31.09 Other frontotemporal dementia

Revise to: G31.09 Other frontotemporal <u>neurocognitive</u>

disorder

Revise from: G31.83 Dementia with Lewy bodies

Revise to: G3183 Neurocognitive disorder with Lewy bodies

Revise from: G3184 Mild cognitive impairment, so stated

Revise to: G3184 Mild cognitive impairment of uncertain or

unknown etiology

Chapter 7- Diseases of the Eye and Adnexa (H00-H59)

No changes

Chapter 8- Diseases of the Ear and Mastoid Process (H60-H95)

No changes

Chapter 9- Diseases of the Circulatory System (100-199)

Additions

20.2	Refractory angina pectoris CC
25.112	Atherosclerosic heart disease of native coronary artery with refractory angina pectoris CC
25.702	Atherosclerosis of coronary artery bypass graft(s), unspecified, with refractory angina pectoris CC
25.712	Atherosclerosis of autologous vein coronary artery bypass graft(s) with refractory angina pectoris CC
25.722	Atherosclerosis of autologous artery coronary artery bypass graft(s) with refractory angina pectoris CC
25.732	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with refractory angina pectoris CC
25.752	Atherosclerosis of native coronary artery of transplanted heart with refractory angina pectoris CC
25.762	Atherosclerosis of bypass graft of coronary artery of transplanted heart with refractory angina pectoris CC
25.792	Atherosclerosis of other coronary artery bypass graft(s) with refractory angina pectoris CC

Chapter 9- Diseases of the Circulatory System (100-199)

I31.31 Malignant pericardial effusion in diseases classified elsewhere CC 131.39 Other pericardial effusion (noninflammatory) CC **I34.81** Nonrheumatic mitral (valve) annulus calcification 134.89 Other nonrheumatic mitral valve disorders 147.20 Ventricular tachycardia, unspecified CC 147.21 **Torsades de pointes CC** 147.29 Other ventricular tachycardia CC 171.010 Dissection of ascending aorta MCC Dissection of aortic arch MCC 171₋011 171.012 Dissection of descending thoracic aorta MCC 171.019 Dissection of thoracic aorta, unspecified MCC **I71.10** Thoracic aortic aneurysm, ruptured, unspecified MCC **Aneurysm of the ascending aorta, ruptured MCC I71.11 I71.12** Aneurysm of the aortic arch, ruptured MCC **I71.13** Aneurysm of the descending thoracic aorta, ruptured MCC

Chapter 9- Diseases of the Circulatory System (100-199)

I71.20	Thoracic aortic aneurysm, without rupture, unspecified
I71.21	Aneurysm of the ascending aorta, without rupture
I71.22	Aneurysm of the aortic arch, without rupture
I71.23	Aneurysm of the descending thoracic aorta, without rupture
I71.30	Abdominal aortic aneurysm, ruptured, unspecified MCC
I71.31	Pararenal abdominal aortic aneurysm, ruptured MCC
I71.32	Juxtarenal abdominal aortic aneurysm, ruptured MCC
I71.33	Infrarenal abdominal aortic aneurysm, ruptured MCC
I71.40	Abdominal aortic aneurysm, without rupture, unspecified
I71.41	Pararenal abdominal aortic aneurysm, without rupture
I71.42	Juxtarenal abdominal aortic aneurysm, without rupture
I71.43	Infrarenal abdominal aortic aneurysm, without rupture
I71.50	Thoracoabdominal aortic aneurysm, ruptured, unspecified MCC
I71.51	Supraceliac aneurysm of the abdominal aorta, ruptured MCC
I71.52	Paravisceral aneurysm of the abdominal aorta, ruptured MCC
I71.60	Thoracoabdominal aortic aneurysm, without rupture, unspecified
I71.61	Supraceliac aneurysm of the abdominal aorta, without rupture
I71.62	Paravisceral aneurysm of the abdominal aorta, without rupture
I77.82	Antineutrophilic cytoplasmic antibody [ANCA] vasculitis

Chapter 9- Diseases of the Circulatory System (100-199)

Deletions

I31.3	Pericardial effusion (noninflammatory)
I34.8	Other nonrheumatic mitral valve disorders
I47.2	Ventricular tachycardia
I71.01	Dissection of thoracic aorta
l71.1	Thoracic aortic aneurysm, ruptured
I71.2	Thoracic aortic aneurysm, without rupture
I71.3	Abdominal aortic aneurysm, ruptured
I71.4	Abdominal aortic aneurysm, without rupture
l71.5	Thoracoabdominal aortic aneurysm, ruptured
I71.6	Thoracoabdominal aortic aneurysm, without rupture

Chapter 10- Diseases of the Respiratory System (J00-J99)

Additions

J95.87 Transfusion-associated dyspnea (TAD) CC

Chapter 11- Diseases of the Digestive System (K00-K95)

Additions

K76.82 Hepatic encephalopathy

*Large list of "code also" notes as well as exclusion notes for this code.

Revisions

Revise from: K35.32 Acute appendicitis with perforation and localized peritonitis, without abscess Revise to: K35.32 Acute appendicitis with perforation, localized peritonitis, and gangrene, without

abscess

Revise from: K35.33 Acute appendicitis with perforation and localized peritonitis, with abscess

Revise to: K35.33 Acute appendicitis with perforation, localized peritonitis, and gangrene, with abscess

Chapter 12- Diseases of the Skin and Subcutaneous Tissue (L00-L99)

No changes

Chapter 13- Diseases of the Musculoskeletal System and Connective Tissue (M00-M99)

Additions	
M51.A0	Intervertebral annulus fibrosus defect, lumbar region, unspecified size
M51.A1	Intervertebral annulus fibrosus defect, small, lumbar region
M51.A2	Intervertebral annulus fibrosus defect, large, lumbar region
M51.A3	Intervertebral annulus fibrosus defect, lumbosacral region, unspecified size
M51.A4	Intervertebral annulus fibrosus defect, small, lumbosacral region
M51.A5	Intervertebral annulus fibrosus defect, large, lumbosacral region
M62.5A0	Muscle wasting and atrophy, not elsewhere classified, back, cervical
M62.5A1	Muscle wasting and atrophy, not elsewhere classified, back, thoracic
M62.5A2	Muscle wasting and atrophy, not elsewhere classified, back, lumbosacral
M62.5A9	Muscle wasting and atrophy, not elsewhere classified, back, unspecified level
M93.004	Unspecified slipped upper femoral epiphysis (nontraumatic), bilateral hips
M93.014	Acute slipped upper femoral epiphysis, stable (nontraumatic), bilateral hips
M93.024	Chronic slipped upper femoral epiphysis, stable (nontraumatic), bilateral hips
M93.034	Acute on chronic slipped upper femoral epiphysis, stable (nontraumatic), bilateral hips
M93.041	Acute slipped upper femoral epiphysis, unstable (nontraumatic), right hip
M93.042	Acute slipped upper femoral epiphysis, unstable (nontraumatic), left hip
M93.043	Acute slipped upper femoral epiphysis, unstable (nontraumatic), unspecified hip

Chapter 13- Diseases of the Musculoskeletal System and Connective Tissue (M00-M99)

```
M93.044 Acute slipped upper femoral epiphysis, unstable (nontraumatic), bilateral hips
M93.051 Acute on chronic slipped upper femoral epiphysis, unstable (nontraumatic), right hip
M93.052 Acute on chronic slipped upper femoral epiphysis, unstable (nontraumatic), left hip
M93.053 Acute on chronic slipped upper femoral epiphysis, unstable (nontraumatic), unspecified hip
M93.054 Acute on chronic slipped upper femoral epiphysis, unstable (nontraumatic), bilateral hips
M93.061 Acute slipped upper femoral epiphysis, unspecified stability (nontraumatic), right hip
M93.062 Acute slipped upper femoral epiphysis, unspecified stability (nontraumatic), left hip
M93.063 Acute slipped upper femoral epiphysis, unspecified stability (nontraumatic), unspecified hip
M93.064 Acute slipped upper femoral epiphysis, unspecified stability (nontraumatic), bilateral hips
M93.071 Acute on chronic slipped upper femoral epiphysis, unspecified stability (nontraumatic), right hip
M93.072 Acute on chronic slipped upper femoral epiphysis, unspecified stability (nontraumatic), left hip
M93.073 Acute on chronic slipped upper femoral epiphysis, unspecified stability (nontraumatic), unspecified hip
M93.074 Acute on chronic slipped upper femoral epiphysis, unspecified stability (nontraumatic), bilateral hips
M96.A1 Fracture of sternum associated with chest compression and cardiopulmonary resuscitation CC
M96.A2 Fracture of one rib associated with chest compression and cardiopulmonary resuscitation CC
M96.A3
        Multiple fractures of ribs associated with chest compression and cardiopulmonary resuscitation CC
M96.A4
        Flail chest associated with chest compression and cardiopulmonary resuscitation MCC
M96.A9
         Other fracture associated with chest compression and cardiopulmonary resuscitation CC
```

Chapter 13- Diseases of the Musculoskeletal System and Connective Tissue (M00-M99)

Revisions

Revise from: M93011 Acute slipped upper femoral epiphysis (nontraumatic), right hip

Revise to: M93011 Acute slipped upper femoral epiphysis, stable (nontraumatic), right hip

Revise from: M93012 Acute slipped upper femoral epiphysis (nontraumatic), left hip

Revise to: M93012 Acute slipped upper femoral epiphysis, stable (nontraumatic), left hip

Revise from: M93013 Acute slipped upper femoral epiphysis (nontraumatic), unspecified hip

Revise to: M93013 Acute slipped upper femoral epiphysis, stable (nontraumatic), unspecified hip

Revise from: M93021 Chronic slipped upper femoral epiphysis (nontraumatic), right hip

Revise to: M93021 Chronic slipped upper femoral epiphysis, <u>stable</u> (nontraumatic), right hip

Chapter 13- Diseases of the Musculoskeletal System and Connective Tissue (M00-M99)

Revise from: M93.022 Chronic slipped upper femoral epiphysis (nontraumatic), left hip

Revise to: M93.022 Chronic slipped upper femoral epiphysis, stable (nontraumatic), left hip

Revise from: M93.023 Chronic slipped upper femoral epiphysis (nontraumatic), unspecified hip

Revise to: M93.023 Chronic slipped upper femoral epiphysis, stable (nontraumatic), unspecified hip

Revise from: M93.031 Acute on chronic slipped upper femoral epiphysis (nontraumatic), right hip

Revise to: M93.031 Acute on chronic slipped upper femoral epiphysis, stable (nontraumatic), right hip

Revise from: M93.032 Acute on chronic slipped upper femoral epiphysis (nontraumatic), left hip

Revise to: M93.032 Acute on chronic slipped upper femoral epiphysis, stable (nontraumatic), left hip

Revise from: M93.033 Acute on chronic slipped upper femoral epiphysis (nontraumatic), unspecified hip

Revise to: M93.033 Acute on chronic slipped upper femoral epiphysis, stable (nontraumatic), unspecified hip

Chapter 14- Diseases of the Genitourinary System (N00-N99)

N14.11 Contrast-induced nephropathy

N14.19 Nephropathy induced by other drugs, medicaments and biological substance

*Code first poisoning then use addl. code to specify adverse effect

N76.82 Fournier disease of vagina and vulva Subcategory N80

Subcategory	Description			
N80.0	Endometriosis of Uterus			
N80.1	Endometriosis of Ovary			
N80.2	Endometriosis of Fallopian Tube			
N80.3	Endometriosis of Pelvic Peritoneum			
N80.4	Endometriosis of Rectovaginal Septum and Vagina			
N80.5	Endometriosis of Intestine			
N80.6	Endometriosis of cutaneous scar			
N80.A	Endometriosis of Bladder and Ureters (New Subcategory)			
N80.B	Endometriosis of Cardiothoracic Space (New Subcategory)			
N80.C	Endometriosis of Abdomen (New Subcategory)			
N80.D	Endometriosis of Pelvic Nerves (New Subcategory)			
N80.8	Other Endometriosis			
N80.9	Endometriosis, Unspecified			

Deletions

N14.1 Nephropathy induced by other drugs, medicaments and biological substances

N80.0 Endometriosis of uterus

N80.1 Endometriosis of ovary

N80.2 Endometriosis of fallopian tube

N80.3 Endometriosis of pelvic peritoneum

N80.4 Endometriosis of rectovaginal septum and vagina

N80.5 Endometriosis of intestine

Chapter 15- Pregnancy, Childbirth and the Puerperium (000-09A)

Additions

Subcategory O35

Subcategory	Description						
035.0	Maternal care for (suspected) central nervous system malformation in fetus (Expansion by type of malformation such as encephalocele or spina bifida)						
035.1	Maternal care for (suspected) chromosomal abnormality in fetus (Expansion by type of abnormality, such as Trisomy 21 and Turner Syndrome)						
Subcategories	O35.2 through O35.9 remain the same						
O35.A	Maternal care for (suspected) other fetal abnormality or damage, fetal facial anomalies (New)						
O35.B	Maternal care for (suspected) other fetal abnormality or damage, fetal cardiac anomalies (New)						
O35.C	Maternal care for (suspected) other fetal abnormality or damage, fetal pulmonary anomalies (New)						
O35.D	Maternal care for (suspected) other fetal abnormality or damage, fetal gastrointestinal anomalies (New)						
O35.E	Maternal care for (suspected) other fetal abnormality or damage, fetal genitourinary anomalies (New)						
O35.F	Maternal care for (suspected) other fetal abnormality or damage, fetal musculoskeletal anomalies of trunk (New)						
O35.G	Maternal care for (suspected) other fetal abnormality or damage, fetal upper extremities abnormalities (New)						
O35.H	Maternal care for (suspected) other fetal abnormality or damage, fetal lower extremities abnormalities (New)						

Chapter 15- Pregnancy, Childbirth and the Puerperium (000-09A)

Deletions

```
O35.0XX0 Maternal care for (suspected) central nervous system malformation in fetus, n/a or unspecified
O35.0XX1 Maternal care for (suspected) central nervous system malformation in fetus, fetus 1
O35.0XX2 Maternal care for (suspected) central nervous system malformation in fetus, fetus 2
O35.0XX3 Maternal care for (suspected) central nervous system malformation in fetus, fetus 3
O35.0XX4 Maternal care for (suspected) central nervous system malformation in fetus, fetus 4
O35.0XX5 Maternal care for (suspected) central nervous system malformation in fetus, fetus 5
O35.0XX9 Maternal care for (suspected) central nervous system malformation in fetus, other fetus
O35.1XX0 Maternal care for (suspected) chromosomal abnormality in fetus, not applicable or unspecified
O35.1XX1 Maternal care for (suspected) chromosomal abnormality in fetus, fetus 1
O35.1XX2 Maternal care for (suspected) chromosomal abnormality in fetus, fetus 2
O35.1XX3 Maternal care for (suspected) chromosomal abnormality in fetus, fetus 3
O35.1XX4 Maternal care for (suspected) chromosomal abnormality in fetus, fetus 4
O35.1XX5 Maternal care for (suspected) chromosomal abnormality in fetus, fetus 5
O35.1XX9 Maternal care for (suspected) chromosomal abnormality in fetus, other fetus
```

Chapter 16- Certain Conditions Originating in the Perinatal Period (P00-P96)

Additions

- P28.30 Primary sleep apnea of newborn, unspecified CC
- P28.31 Primary central sleep apnea of newborn CC
- P28.32 Primary obstructive sleep apnea of newborn CC
- P28.33 Primary mixed sleep apnea of newborn CC
- P28.39 Other primary sleep apnea of newborn CC
- P28.40 Unspecified apnea of newborn CC
- P28.41 Central neonatal apnea of newborn CC
- P28.42 Obstructive apnea of newborn CC
- P28.43 Mixed neonatal apnea of newborn CC
- P28.49 Other apnea of newborn CC

Deletions

P28.3 Primary sleep apnea of newborn

P28.4 Other apnea of newborn

Chapter 17- Congenital Malformations, Deformations and Chromosomal Abnormalities (Q00-Q99)

Addition	<u>is</u>	<u>Deletions</u>
Q21.10	Atrial septal defect, unspecified CC	Q21.1 Atrial septal defect
Q21.11	Secundum atrial septal defect CC	
Q21.12	Patent foramen ovale CC	Q21.2 Atrioventricular septal
Q21.13	Coronary sinus atrial septal defect CC	defect
Q21.14	Superior sinus venosus atrial septal defect CC	
Q21.15	Inferior sinus venosus atrial septal defect CC	Q85.8 Other phakomatoses, not
Q21.16	Sinus venosus atrial septal defect, unspecified CC	elsewhere classified
Q21.19	Other specified atrial septal defect CC	
Q21.20	Atrioventricular septal defect, unspecified as to partial or complete CC	
Q21.21	Partial atrioventricular septal defect CC	
Q21.22	Transitional atrioventricular septal defect CC	
Q21.23	Complete atrioventricular septal defect CC	
Q85.81	PTEN tumor syndrome CC	
Q85.82	Other Cowden syndrome CC	
Q85.83	Von Hippel-Lindau syndrome CC	
Q85.89	Other phakomatoses, not elsewhere classified CC confidential • Do not distribute • @Copyright Vitalware, LLC. All rights reserved	l.

Chapter 18- Symptoms, Signs and Abnormal Clinical and Laboratory Findings, Not Elsewhere Classified (R00-R99)

No changes

Chapter 19- Injury, Poisoning and Certain Other Consequences of External Causes (S00-T88)

- 3 Changes to Category S06, Intracranial Injury:
- Addition of codes for Primary Blast Injury (\$06.8A0-\$06.8A9)
- Addition of codes for loss of consciousness with status unknown (S06.0- to S06.9-)
- Addition of an inclusion term for "brief" loss of consciousness (S06.0- to S06.9-)

Many of these changes with a 7th character of A for Initial Treatment are CC's and MCC's

Chapter 19- Injury, Poisoning and Certain Other Consequences of External Causes (S00-T88)

Additions

T43.65-

* Add 7th character of A (initial encounter), D (subsequent encounter), or S (sequela)

T43651- Poisoning by methamphetamines accidental (unintentional)

T43652- Poisoning by methamphetamines intentional self-harm

T43653- Poisoning by methamphetamines, assault

T43654- Poisoning by methamphetamines, undetermined

T43655- Adverse effect of methamphetamines

T43656- Underdosing of methamphetamines

Chapter 20- External Causes of Morbidity (V00-Y99)

Additions

Hundreds of codes for injuries involving electric bicycles have been added to categories V20-V29 (the categories that involve motorcycles, not bicycles).

Caught, crushed, jammed or pinched between a moving and stationary object, initial encounter

Caught, crushed, jammed or pinched between a moving and stationary object, subsequent encounter

W23.2XXD object, subsequent encounter

Caught, crushed, jammed or pinched between a moving and stationary W23.2XXS object, sequela

Chapter 21- Factors Influencing Health Status and Contact with Services (Z00-Z99)

Z03.83	Encounter for observation for suspected conditions related to home physiologic monitoring device ruled out
Z59.82	Transportation insecurity
Z59.86	Financial insecurity
Z59.87	Material hardship
Z 71.87	Encounter for pediatric-to-adult transition counseling
Z71.88	Encounter for counseling for socioeconomic factors
Z72.823	Risk of suffocation (smothering) under another while sleeping
Z79.60	Long term (current) use of unspecified immunomodulators and immunosuppressants
Z79.61	Long term (current) use of immunomodulator
Z79.620	Long term (current) use of immunosuppressive biologic
Z79.621	Long term (current) use of calcineurin inhibitor
Z79.622	Long term (current) use of Janus kinase inhibitor
Z79.623	Long term (current) use of mammalian target of rapamycin (mTOR) inhibitor
Z79624	Long term (current) use of inhibitors of nucleotide synthesis
Z79.630	Long term (current) use of alkylating agent
Z79.631	Long term (current) use of antimetabolite agent
Z79.632	Long term (current) use of antitumor antibiotic
Z79.633	Long term (current) use of mitotic inhibitor
Z79.634	Long term (current) use of topoisomerase inhibitor
Z79.64	Long term (current) use of myelosuppressive agent
Z79.69	Long term (current) use of other immunomodulators and immunosuppressants
Z79.85	Long-term (current) use of injectable non-insulin antidiabetic drugs
Z87.61	Personal history of (corrected) necrotizing enterocolitis of newborn
Z87.68	Personal history of other (corrected) conditions arising in the perinatal period
Z87.731	Personal history of (corrected) tracheoesophageal fistula or atresia
Z87.732	Personal history of (corrected) persistent cloaca or cloacal malformations
	Confidential • Do not distribute • ©Copyright Vitalware, LLC. All rights reserved.

Chapter 21- Factors Influencing Health Status and Contact with Services (Z00-Z99)

Z87.760	Personal history of (corrected) congenital diaphragmatic hernia or other congenital diaphragm malformations
Z87.761	Personal history of (corrected) gastroschisis
Z87.762	Personal history of (corrected) prune belly malformation
Z87.763	Personal history of other (corrected) congenital abdominal wall malformations
Z87.768	Personal history of other specified (corrected) congenital malformations of integument, limbs and musculoskeletal system
Z91.110	Patient's noncompliance with dietary regimen due to financial hardship
Z 91.118	Patient's noncompliance with dietary regimen for other reason
Z 91.119	Patient's noncompliance with dietary regimen due to unspecified reason
Z91.190	Patient's noncompliance with other medical treatment and regimen due to financial hardship
Z 91.198	Patient's noncompliance with other medical treatment and regimen for other reason
Z 91.199	Patient's noncompliance with other medical treatment and regimen due to unspecified reason
Z91.A10	Caregiver's noncompliance with patient's dietary regimen due to financial hardship
Z91.A18	Caregiver's noncompliance with patient's dietary regimen for other reason
Z91.A20	Caregiver's intentional underdosing of patient's medication regimen due to financial hardship
Z91.A28	Caregiver's intentional underdosing of medication regimen for other reason
Z91.A3	Caregiver's unintentional underdosing of patient's medication regimen
Z91.A4	Caregiver's other noncompliance with patient's medication regimen
Z91.A5	Caregiver's noncompliance with patient's renal dialysis
Z91.A9	Caregiver's noncompliance with patient's other medical treatment and regimen

Chapter 21- Factors Influencing Health Status and Contact with Services (Z00-Z99)

Deletions

Z87.76 Personal history of (corrected) congenital malformations of integument, limbs and musculoskeletal system

Z91.11 Patient's noncompliance with dietary regimen

Z91.19 Patient's noncompliance with other medical treatment and regimen

General Coding Guidelines

Documentation by Clinicians Other than the Patient's Provider

Code assignment is based on the documentation by the patient's provider (i.e., physician or other qualified healthcare practitioner legally accountable for establishing the patient's diagnosis). There are a few exceptions when code assignment may be based on medical record documentation from clinicians who are not the patient's provider (i.e., physician or other qualified healthcare practitioner legally accountable for establishing the patient's diagnosis). In this context, "clinicians" other than the patient's provider refer to healthcare professionals permitted, based on regulatory or accreditation requirements or internal hospital policies, to document in a patient's official medical record.

These exceptions include codes for:

- Body Mass Index (BMI)
- Depth of non-pressure chronic ulcers
- Pressure ulcer stage
- Coma scale
- NIH stroke scale (NIHSS)
- Social determinants of health (SDOH)
- Laterality
- Blood alcohol level
- **Underimmunization status**



Documentation of Complications of Care

Code assignment is based on the provider's documentation of the relationship between the condition and the care or procedure, unless otherwise instructed by the classification. The guideline extends to any complications of care, regardless of the chapter the code is located in. It is important to note that not all conditions that occur during or following medical care or surgery are classified as complications. There must be a cause-and-effect relationship between the care provided and the condition, and the documentation must support that the condition is clinically significant. It is not necessary for the provider to explicitly document the term "complication." For example, if the condition alters the course of the surgery as documented in the operative report, then it would be appropriate to report a complication code. Query the provider for clarification if the documentation is not clear as to the relationship between the condition and the care or procedure.

Chapter-Specific Coding Guidelines

Human Immunodeficiency Virus (HIV) Infections

Selection and sequencing of HIV codes

(a) Patient admitted for HIV-related condition If a patient is admitted for an HIV-related condition, the principal diagnosis should be B20, Human immunodeficiency virus [HIV] disease followed by additional diagnosis codes for all reported HIV-related conditions.

An exception to this guideline is if the reason for admission is hemolytic-uremic syndrome associated with HIV disease. Assign code D59.31, Infection-associated hemolytic-uremic syndrome, followed by code B20, Human immunodeficiency virus [HIV] disease.

Sepsis, Severe Sepsis, and Septic Shock Infections resistant to antibiotics Hemolytic-uremic syndrome associated with sepsis

If the reason for admission is hemolytic-uremic syndrome that is associated with sepsis, assign code D59.31, Infection-associated hemolytic-uremic syndrome, as the principal diagnosis. Codes for the underlying systemic infection and any other conditions (such as severe sepsis) should be assigned as secondary diagnoses.

Chapter 2: Neoplasms (C00-D49)

Admission/Encounter for treatment of primary site

If the malignancy <u>is chiefly responsible for occasioning the patient</u> <u>admission/encounter and treatment is directed at the primary site</u>, designate the <u>primary</u> malignancy as the principal/<u>first-listed</u> diagnosis.

The only exception to this guideline is if the administration of chemotherapy, immunotherapy or external beam radiation therapy is chiefly responsible for occasioning the admission/encounter. In that case, assign the appropriate Z51.-- code as the first-listed or principal diagnosis, and the underlying diagnosis or problem for which the service is being performed as a secondary diagnosis.

Secondary malignant neoplasm of lymphoid tissue

When a malignant neoplasm of lymphoid tissue metastasizes beyond the lymph nodes, a code from categories C81-C85 with a final character "9" should be assigned identifying "extranodal and solid organ sites" rather than a code for the secondary neoplasm of the affected solid organ. For example, for metastasis of B-cell lymphoma to the lung, brain and left adrenal gland, assign code C83.39, Diffuse large B-cell lymphoma, extranodal and solid organ sites.

Chapter 5: Mental, Behavioral and Neurodevelopmental disorders (F01 – F99)

Dementia

The ICD-10-CM classifies dementia (categories F01, F02, and F03) on the basis of the etiology and severity (unspecified, mild, moderate or severe). Selection of the appropriate severity level requires the provider's clinical judgment and codes should be assigned only on the basis of provider documentation (as defined in the Official Guidelines for Coding and Reporting), unless otherwise instructed by the classification. If the documentation does not provide information about the severity of the dementia, assign the appropriate code for unspecified severity. If a patient is admitted to an inpatient acute care hospital or other inpatient facility setting with dementia at one severity level and it progresses to a higher severity level, assign one code for the highest severity level reported during the stay.

Chapter 15: Pregnancy, Childbirth, and the Puerperium (O00-O9A)

Completed weeks of gestation

In ICD-10-CM, "completed" weeks of gestation refers to full weeks. For example, if the provider documents gestation at 39 weeks and 6 days, the code for 39 weeks of gestation should be assigned, as the patient has not yet reached 40 completed weeks.



Termination of Pregnancy and Spontaneous abortions

Hemorrhage following elective abortion

For hemorrhage post elective abortion, assign code O04.6, Delayed or excessive hemorrhage following (induced) termination of pregnancy. Do not assign code O72.1, Other immediate postpartum hemorrhage, as this code should not be assigned for post abortion conditions. Do not assign code Z33.2, Encounter for elective termination of pregnancy, when the patient experiences a complication post elective abortion.

Adverse Effects, Poisoning, Underdosing and Toxic Effects

Underdosing

Documentation of a change in the patient's condition is not required in order to assign an underdosing code. Documentation that the patient is taking less of a medication than is prescribed or discontinued the prescribed medication is sufficient for code assignment.

Social Determinants of Health

Codes describing problems or risk factors related to social determinants of health (SDOH) should be assigned when this information is documented.

Assign as many SDOH codes as are necessary to describe all of the problems or risk factors. These codes should be assigned only when the documentation specifies that the patient has an associated problem or risk factor. For example, not every individual living alone would be assigned code Z60.2, Problems related to living alone.

Additions, Deletions, Revisions, and Guideline Updates

Change Summary Table

2022 Total	New Codes	Revised Titles	Deleted Codes	2023 Total
78,229	331	0	64	78,496

ICD-10-PCS Code FY 2023 Totals, By Section

Medical and Surgical	68,024
Obstetrics	304
Placement	861
Administration	1,257
Measurement and Monitoring	422
Extracorporeal or Systemic Assistance and Performance	51
Extracorporeal or Systemic Therapies	46
Osteopathic	100
Other Procedures	78
Chiropractic	90
Imaging	2,978
Nuclear Medicine	463
Radiation Therapy	2,056
Physical Rehabilitation and Diagnostic Audiology	1,380
Mental Health	30
Substance Abuse Treatment	59
New Technology	297
Total	78,496

2023 ICD-10-PCS Conversion Table:

https://www.cms.gov/medicare/icd-10/2023-icd-10-pcs

vare, LLC. All rights reserved.

Laser Interstitial Thermal Therapy (LITT)

- Added to Destruction tables in 7 body systems.
- New qualifier of 3, Laser Interstitial Thermal Therapy, has been added to the following tables:
 - 005- Central Nervous (Brain and Spinal Cord only)
 - **OB5- Respiratory System (Lung lobes only)**
 - **0D5- Gastrointestinal System**
 - **0F5- Hepatobiliary System and Pancreas (Liver, Gallbladder and Pancreas only)**
 - **0G5- Endocrine System**
 - **0H5- Skin and Breast (Breast only)**
 - **0V5- Male Reproductive (Prostate only)**

Two manufacturers: Visualase™ and Neuroblate®

All LITT codes deleted from Radiation Therapy section.



00D - Medical and Surgical/ Central Nervous System and Cranial Nerves/Extraction

Section	0	Medic	Medical and Surgical			
Body System	0	Centr	Central Nervous System and Cranial Nerves			
Operation	D	Extra	Extraction: Pulling or stripping out or off all or a portion of a body part by the use of force			
Body Part		Approach Device Qualifier			Qualifier	
0 Brain 1 Cerebral Meninge 2 Dura Mater 7 Cerebral Hemisph C Cerebellum			Open Percutaneous Percutaneous Endoscopic	Z No Device	Z No Qualifier	

Body part value, C, Cerebellum has been added.

```
00DC0ZZ Extraction of Cerebellum, Open Approach
00DC3ZZ Extraction of Cerebellum, Percutaneous Approach
00DC4ZZ Extraction of Cerebellum, Percutaneous Endoscopic Approach
```

CUSA, Cavitron Ultrasonic Surgical Aspiration

XOH - New Technology/Nervous System/ Insertion

Section	X	New	ew Technology				
Body System	0	Nervo	vous System				
Operation	Н		ertion: Putting in a nonbiological appliance that monitors, assists, performs, or prevents a siological function but does not physically take the place of a body part				
Body Part			Approach	Device / Substance / Technology	Qualifier		
K Sphenopalatin	e Gan	glion	3 Percutaneous	Q Neurostimulator Lead	8 New Technology Group 8		
Q Vagus Nerve		-	3 Percutaneous	R Neurostimulator Lead with Paired Stimulation System	8 New Technology Group 8		

Added two new neurostimulator leads: K, Sphenopalatine Ganglion and Q, **Vagus Nerve**

Insertion of Neurostimulator Lead into Sphenopalatine Ganglion, Percutaneous Approach,

X0HK3Q8 New Technology Group 8

Insertion of Neurostimulator Lead with Paired Stimulation System into Vagus Nerve,

X0HQ3R8 Percutaneous Approach, New Technology Group 8

*Code 0JH60MZ, Insertion of stimulator generator into chest subcutaneous tissue and fascia, open approach is also assigned with X0HQ3R8
Confidential • Do not distribute • ©Copyright Vitalware, LLC. All rights reserved.

X0Z- New Technology/Nervous System/Other Procedures

Section	X	New	lew Technology			
Body System	0	Nervo	ervous System			
Operation	Z	Other	other Procedures: Methodologies which attempt to remediate or cure a disorder or disease			
Body Part			Approach	Device / Substance / Technology	Qualifier	
Prefrontal Cortex			X External	1 Computer-assisted Transcranial Magnetic Stimulation	8 New Technology Group 8	

Added device/substance/technology value 1, Computerassisted Transcranial Magnetic Stimulation

Computer-assisted Transcranial Magnetic Stimulation of X0Z0X18 Prefrontal Cortex, New Technology Group 8

Magnus Neuromodulation System

X2A- New Technology/Cardiovascular System/Assistance

Section	X Ne	ew Technology		
Body System	2 Ca	ardiovascular System		
Operation	A As	sistance: Taking over a por	tion of a physiological function by ext	racorporeal means
Body Part		Approach	Device / Substance / Technology	Qualifier
5 Innominate Arte Common Carotid	ery and Le Artery	eft 3 Percutaneous	Cerebral Embolic Filtration, Dual Filter	2 New Technology Group 2
6 Aortic Arch		3 Percutaneous	2 Cerebral Embolic Filtration, Single Deflection Filter	5 New Technology Group 5
7 Coronary Sinus		3 Percutaneous	5 Intermittent Coronary Sinus Occlusion	8 New Technology Group 8
H Common Carot Right J Common Caroti Left		3 Percutaneous	3 Cerebral Embolic Filtration, Extracorporeal Flow Reversal Circuit	6 New Technology Group 6

Device/Substance/Technology value 5, Intermittent coronary sinus occlusion added.

X2A7358 Intermittent Coronary Sinus Occlusion, Percutaneous Approach, New Technology Group 8


• PICSOTM system www.dicardiology.com/videos/video-device-aids-prevention-reperfusion-injury-following-pci

04L – Medical and Surgical/Lower Arteries/Occlusion

Section	0	Medi	Medical and Surgical			
Body System	4	Lowe	r Arteries			
Operation	L	Occlu	ision: Completely closing an or	ifice or the lumen of a tubular b	ody part	
Body Part			Approach	Device	Qualifier	
E Internal Iliac Artery, Right			Open Percutaneous Percutaneous Endoscopic	C Extraluminal Device D Intraluminal Device Z No Device	T Uterine Artery, Right V Prostatic Artery, Right Z No Qualifier	
F Internal Iliac Artery, Left			Open Percutaneous Percutaneous Endoscopic	C Extraluminal Device D Intraluminal Device Z No Device	U Uterine Artery, Left W Prostatic Artery, Left Z No Qualifier	

Addition of Qualifiers V, Prostatic Artery, Right and W, Prostatic Artery,

Left



04L - Medical and Surgical/Lower Arteries/Occlusion (continued)

04LE0CV	Occlusion of Right Prostatic Artery with Extraluminal Device, Open Approach
04LE0DV	Occlusion of Right Prostatic Artery with Intraluminal Device, Open Approach
04LE0ZV	Occlusion of Right Prostatic Artery, Open Approach
04LE3CV	Occlusion of Right Prostatic Artery with Extraluminal Device, Percutaneous Approach
04LE3DV	Occlusion of Right Prostatic Artery with Intraluminal Device, Percutaneous Approach
04LE3ZV	Occlusion of Right Prostatic Artery, Percutaneous Approach
04LE4CV	Occlusion of Right Prostatic Artery with Extraluminal Device, Percutaneous Endoscopic Approach
04LE4DV	Occlusion of Right Prostatic Artery with Intraluminal Device, Percutaneous Endoscopic Approach
04LE4ZV	Occlusion of Right Prostatic Artery, Percutaneous Endoscopic Approach
04LF0CW	Occlusion of Left Prostatic Artery with Extraluminal Device, Open Approach
04LF0DW	Occlusion of Left Prostatic Artery with Intraluminal Device, Open Approach
04LF0ZW	Occlusion of Left Prostatic Artery, Open Approach
04LF3CW	Occlusion of Left Prostatic Artery with Extraluminal Device, Percutaneous Approach
04LF3DW	Occlusion of Left Prostatic Artery with Intraluminal Device, Percutaneous Approach
04LF3ZW	Occlusion of Left Prostatic Artery, Percutaneous Approach
04LF4CW	Occlusion of Left Prostatic Artery with Extraluminal Device, Percutaneous Endoscopic Approach
04LF4DW	Occlusion of Left Prostatic Artery with Intraluminal Device, Percutaneous Endoscopic Approach
04LF4ZW	Occlusion of Left Prostatic Artery, Percutaneous Endoscopic Approach

ODX – Medical and Surgical/Gastrointestinal System/Transfer

Section	0	Medical and Surgical				
Body System	D	Gastrointestinal System				
Operation X Transfer: Moving, without taking out, all or a portion of a body part to another lo						
Body Part		Approach	Device	Qualifier		
6 Stomach		Open Percutaneous Endo	z No Device	5 Esophagus		
8 Small Intestine		Open Percutaneous Endo	z No Device	5 Esophagus B Bladder C Ureter, Right D Ureter, Left F Ureters, Bilateral		
E Large Intestine		Open Percutaneous Endo	z No Device	5 Esophagus 7 Vagina B Bladder		


New Qualifiers added to describe transfer destinations:

B = Bladder

C = Right ureter

D = Left ureter

F = Bilateral ureters



ODX – Medical and Surgical/Gastrointestinal System/Transfer

```
ODX80ZB Transfer Small Intestine to Bladder, Open Approach
ODX80ZC Transfer Small Intestine to Right Ureter, Open Approach
ODX80ZD Transfer Small Intestine to Left Ureter, Open Approach
ODX80ZF Transfer Small Intestine to Bilateral Ureters, Open Approach
ODX80ZF Transfer Small Intestine to Bilateral Ureters, Open Approach
ODX84ZB Transfer Small Intestine to Bladder, Percutaneous Endoscopic Approach
ODX84ZC Transfer Small Intestine to Right Ureter, Percutaneous Endoscopic Approach
ODX84ZD Transfer Small Intestine to Left Ureter, Percutaneous Endoscopic Approach
ODX84ZF Transfer Small Intestine to Bilateral Ureters, Percutaneous Endoscopic Approach
ODX84ZF Transfer Small Intestine to Bilateral Ureters, Percutaneous Endoscopic Approach
ODXEOZB Transfer Large Intestine to Bladder, Open Approach
ODXE4ZB Transfer Large Intestine to Bladder, Percutaneous Endoscopic Approach
```

Confidential • Do not distribute • @Copyright Vitalware, LLC. All rights reserved.

XF5 – New Technology/Hepatobiliary System and Pancreas/Destruction

Section	X	New Technology			
Body System	F	Hepatobiliary System and Pancreas			
Operation	5	Destruction: Physical erad force, or a destructive age	ication of all or a portion of a body	part by the direct use of energy,	
Body Part		Approach	Device / Substance / Technology	Qualifier	
0 Liver 1 Liver, Right Lobe 2 Liver, Left Lobe		X External	Ultrasound-guided Cavitation	8 New Technology Group 8	

Added new Device/Substance/Technology value of 0, Ultrasound-guided Cavitation

	Destruction of Liver using Ultrasound-guided Cavitation, External Approach, New Technology
XF50X08	Group 8
	Destruction of Right Lobe Liver using Ultrasound-guided Cavitation, External Approach, New
XF51X08	Technology Group 8
	Destruction of Left Lobe Liver using Ultrasound-guided Cavitation, External Approach, New
XF52X08	Technology Group 8

Histosonics®

ONP - Medical and Surgical/ Head and Facial Bones/ Removal

Section 0 Medical and Surgical						
Body System N	Head and Facial Bones					
Operation P	Removal: Taking out or off a device	from a body part				
Body Part	Approach	Device	Qualifier			
0 Skull	0 Open	O Drainage Device Infusion Device Internal Fixation Device External Fixation Device Autologous Tissue Substitute J Synthetic Substitute K Nonautologous Tissue Substitute M Bone Growth Stimulator N Neurostimulator Generator Hearing Device	Z No Qualifier			
0 Skull	3 Percutaneous 4 Percutaneous Endoscopic	O Drainage Device Infusion Device Internal Fixation Device External Fixation Device Autologous Tissue Substitute J Synthetic Substitute K Nonautologous Tissue Substitute M Bone Growth Stimulator Hearing Device	Z No Qualifier			
0 Skull	X External	Drainage Device Infusion Device Internal Fixation Device External Fixation Device Bone Growth Stimulator Hearing Device	Z No Qualifier			
B Nasal Bone W Facial Bone	Open Percutaneous Percutaneous Endoscopic	O Drainage Device Internal Fixation Device Autologous Tissue Substitute J Synthetic Substitute K Nonautologous Tissue Substitute M Bone Growth Stimulator	Z No Qualifier			
B Nasal Bone W Facial Bone	X External	Drainage Device Internal Fixation Device Bone Growth Stimulator	Z No Qualifier			

	Removal of Infusion Device from Skull,
0NP003Z	Open Approach
	Removal of Infusion Device from Skull,
0NP033Z	Percutaneous Approach
	Removal of Infusion Device from Skull,
0NP043Z	Percutaneous Endoscopic Approach
	Removal of Infusion Device from Skull,
0NP0X3Z	External Approach

ORW - Medical and Surgical/ Head and Facial Bones/ Revision

Section	0 Medical and Surg	ical			
Body System	N Head and Facial E	Bones			
Operation	W Revision: Correcti of a displaced dev	ing, to the extent possible, a portion of a malfurice	unctioning device or the position		
Body Part	Approach	Device	Qualifier		
0 Skull	0 Open	O Drainage Device 3 Infusion Device 4 Internal Fixation Device 5 External Fixation Device 7 Autologous Tissue Substitute J Synthetic Substitute K Nonautologous Tissue Substitute M Bone Growth Stimulator N Neurostimulator General S Hearing Device	r	0NW003Z 0NW033Z	Revision of Infusion Device in Skull, Open Approach Revision of Infusion Device in Skull, Percutaneous Approach
0 Skull	3 Percutane 4 Percutane X External			0NW043Z - 0NW0X3Z	Revision of Infusion Device in Skull,
B Nasal Bone W Facial Bone	0 Open 3 Percutane 4 Percutane X External	eous eous Endoscopic 4 Internal Fixation Device 7 Autologous Tissue Substitute J Synthetic Substitute K Nonautologous Tissue Substitute M Bone Growth Stimulator	Z No Qualifier	UNVUX3Z	External Approach

XKU – New Technology/ Muscles, Tendons, Bursae and Ligaments/ Supplement

Section	X	New	New Technology				
Body System	K	Musc	eles, Tendons, Bursa	e and Liga	ments		
Operation	U	Supplement: Putting in or on biological or synthetic material that physically reinforces and/or augments the function of a portion of a body part					
			Device / Substance / Technology	Qualifier			
C Upper Spine Bursa and Ligament D Lower Spine Bursa and Ligament		0 Open		6 Posterior Vertebral Tether	8 New Technology Group 8		

XKUC068

XKUD068

Supplement Upper Spine Bursa and Ligament with Posterior Vertebral Tether, Open Approach, New Technology Group 8 Supplement Lower Spine Bursa and Ligament with Posterior Vertebral Tether, Open Approach, New Technology Group 8

LigaPASS 2.0™

XRH – New Technology/ Joints/ Insertion

Section	X	New 7	New Technology					
Body System	R	Joints	3					
Operation	Н		nsertion: Putting in a nonbiological appliance that monitors, assists, performs, or prevents a physiological function but does not physically take the place of a body part					
Body Part Approach Device / Substance / Qualifier Technology								
B Lumbar Vertebral Joint 0 Open D Lumbosacral Joint				1 Posterior Spinal Motion Preservation Device	8 New Technology Group 8			

Insertion of Posterior Spinal Motion Preservation Device into
XRHB018 Lumbar Vertebral Joint, Open Approach, New Technology Group 8
Insertion of Posterior Spinal Motion Preservation Device into
XRHD018 Lumbosacral Joint, Open Approach, New Technology Group 8

TOPS™ System from Premia Spine

https://www.bing.com/videos/search?q=TOPS%e2%84%a2+System+from+Premia+Spine&docid=607990562968531528&mid=AC06924CF047AF7ECFEBAC06924CF047AF7ECFEB&view=detail&FORM=VIRE

XNH - New Technology/Bones/Insertion

Section	X	New Technology	New Technology				
Body System	N	Bones					
Operation	Н	Insertion: Putting in a nonbiological appliance that monitors, assists, performs, or prevents a physiological function but does not physically take the place of a body part					
Body Part Approach Device / Substance / Qualifier Technology							
6 Pelvic Bone, Right 7 Pelvic Bone, Left 0 Open 3 Percutaneous			5 Internal Fixation Device with Tulip Connector	8 New Technology Group 8			

	Insertion of Internal Fixation Device with Tulip Connector into Right Pelvic Bone,
XNH6058	Open Approach, New Technology Group 8
	Insertion of Internal Fixation Device with Tulip Connector into Right Pelvic Bone,
XNH6358	Percutaneous Approach, New Technology Group 8
	Insertion of Internal Fixation Device with Tulip Connector into Left Pelvic Bone,
XNH7058	Open Approach, New Technology Group 8
	Insertion of Internal Fixation Device with Tulip Connector into Left Pelvic Bone,
XNH7358	Percutaneous Approach, New Technology Group 8

iFuse Bedrock Granite Device

XRG - New Technology/Joints/Fusion

Section	X	New '	New Technology					
Body System	R	Joints	3					
Operation	G	Fusio immo		an articular body part rendering	ng the articular body part			
Body Part			Approach	Device / Substance / Technology	Qualifier			
A Thoracolumbar Vertebral Joint B Lumbar Vertebral Joint C Lumbar Vertebral Joints, 2 or more D Lumbosacral Joint			Open Percutaneous Percutaneous Endoscopic	R Interbody Fusion Device, Customizable	7 New Technology Group 7			
			0 Open 3 Percutaneous	5 Internal Fixation Device with Tulip Connector	8 New Technology Group 8			

	Fusion of Right Sacroiliac Joint using Internal Fixation Device with Tulip Connector, Open
XRGE058	Approach, New Technology Group 8
	Fusion of Right Sacroiliac Joint using Internal Fixation Device with Tulip Connector,
XRGE358	Percutaneous Approach, New Technology Group 8
	Fusion of Left Sacroiliac Joint using Internal Fixation Device with Tulip Connector, Open
XRGF058	Approach, New Technology Group 8
	Fusion of Left Sacroiliac Joint using Internal Fixation Device with Tulip Connector,
XRGF358	Percutaneous Approach, New Technology Group 8
	Confidential • Do not distribute • ©Copyright Vitalware, LLC. All rights reserved.

XRR - New Technology/ Joints/ Replacement

Section	X	New Technology	New Technology					
Body System	R	Joints						
Operation	R		Replacement: Putting in or on biological or synthetic material that physically takes the place and/or function of all or a portion of a body part					
Body Part Approach Device / Substance / Qualifier Technology			Qualifier					
G Knee Joint, Right H Knee Joint, Left		0 Open	L Synthetic Substitute, Lateral Meniscus M Synthetic Substitute, Medial Meniscus	8 New Technology Group 8				



	Replacement of Right Knee Joint with Synthetic Substitute, Lateral Meniscus, Open
XRRG0L8	Approach, New Technology Group 8
	Replacement of Right Knee Joint with Synthetic Substitute, Medial Meniscus, Open
XRRG0M8	Approach, New Technology Group 8
	Replacement of Left Knee Joint with Synthetic Substitute, Lateral Meniscus, Open
XRRH0L8	Approach, New Technology Group 8
	Replacement of Left Knee Joint with Synthetic Substitute, Medial Meniscus, Open
XRRH0M8	Approach, New Technology Group 8

• NUsurface® Meniscus Replacement https://www.youtube.com/watch?v=tB8aWsXbGhg

0W9 – Medical and Surgical/ General Anatomical Regions/ Drainage

Body System W Ana	dical and Surgical tomical Regions, General inage: Taking or letting out fluid	s and/or gases from a body	y part		
Body Part	Approach	Device	Qualifier		
0 Head 1 Cranial Cavity 2 Face 3 Oral Cavity and Throat 4 Upper Jaw 5 Lower Jaw 8 Chest Wall	Open Percutaneous Percutaneous Endoscopic	Drainage Device	Z No Qualifier	0W9670Z	Drainage of Neck with Drainage Device, Via Natural or Artificial Opening
9 Pleural Cavity, Right B Pleural Cavity, Left C Mediastinum D Pericardial Cavity F Abdominal Wall G Peritoneal Cavity				0W967ZX	Drainage of Neck, Via Natural or Artificial Opening, Diagnostic
H Retroperitoneum K Upper Back L Lower Back M Perineum, Male N Perineum, Female				0W967ZZ	Drainage of Neck, Via Natural or Artificial Opening
0 Head 1 Cranial Cavity 2 Face 3 Oral Cavity and Throat 4 Upper Jaw 5 Lower Jaw 8 Chest Wall	Open Percutaneous Percutaneous Endoscopic	Z No Device	X Diagnostic Z No Qualifier	0W9680Z	Drainage of Neck with Drainage Device, Via Natural or Artificial Opening Endoscopic
9 Pleural Cavity, Right B Pleural Cavity, Left C Mediastinum D Pericardial Cavity F Abdominal Wall G Peritoneal Cavity H Retroperitoneum				0W968ZX	Drainage of Neck, Via Natural or Artificial Opening Endoscopic, Diagnostic
K Upper Back L Lower Back M Perineum, Male N Perineum, Female				0W968ZZ	Drainage of Neck, Via Natural or Artificial Opening Endoscopic
6 Neck J Pelvic Cavity	Open Percutaneous Percutaneous Endoscopic Via Natural or Artificial Opening Via Natural or Artificial Opening Endoscopic	Drainage Device	Z No Qualifier	Vitalware, LLC. All rights i	reserved.

3E0 - Administration/ Physiological Systems and Anatomical Regions/ Introduction

Section	3	Administration					
Body System	E	Physiological Systems and Anatomical Regions					
Operation	0		troduction: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic ibstance except blood or blood products				
Body System / R	Region	Approach	Substance	Qualifier			
V Bones		0 Open	G Other Therapeutic Substance	B Recombinant Bone Morphogenetic Protein C Other Substance			
V Bones		3 Percutaneous	Antineoplastic	5 Other Antineoplastic M Monoclonal Antibody			
V Bones		3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective			
V Bones		3 Percutaneous	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier			
V Bones		3 Percutaneous	G Other Therapeutic Substance	B Recombinant Bone Morphogenetic Protein C Other Substance			
V Bones		4 Percutaneous Endosco	pic G Other Therapeutic	C Other Substance			

 AccuFill Calcium Phosphate



3E0V0GC Introduction of Other Therapeutic Substance into Bones, Open Approach
3E0V4GC Introduction of Other Therapeutic Substance into Bones, Percutaneous Endoscopic Approach

3E0 - Administration/ Physiological Systems and Anatomical Regions/ Introduction

Section 3	Administration				
Body System E	Physiological Systems and A	natomical Regions			
Operation 0		ntroduction: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylact ubstance except blood or blood products			
Body System / Region	Approach	Substance	Qualifier		
3 Peripheral Vein	3 Percutaneous	G Other Therapeutic Substance	C Other Substance N Blood Brain Barrier Disruption Q Glucarpidase R Other Therapeutic Monoclonal Antibody		
4 Central Vein	3 Percutaneous	G Other Therapeutic Substance	C Other Substance N Blood Brain Barrier Disruption Q Glucarpidase R Other Therapeutic Monoclonal Antibody		

Introduction of Other Therapeutic Monoclonal Antibody into Peripheral Vein,
3E033GR Percutaneous Approach
Introduction of Other Therapeutic Monoclonal Antibody into Central Vein,
3E043GR Percutaneous Approach

Confidential • Do not distribute • @Copyright Vitalware, LLC. All rights reserved.

02R- Medical and Surgical/ Heart and Great Vessels/ Replacement

Section Body System Operation	0 2 R	Heart	cal and Surgical and Great Vessels acement: Putting in or on biolog or function of all or a portion of		it physically takes the place
Body Part			Approach	Device	Qualifier
F Aortic Valve			0 Open 4 Percutaneous Endoscopic	7 Autologous Tissue Substitute J Synthetic Substitute K Nonautologous Tissue Substitute	Z No Qualifier
F Aortic Valve			Open Percutaneous Endoscopic	8 Zooplastic Tissue	N Rapid Deployment Technique Z No Qualifier
F Aortic Valve			3 Percutaneous	7 Autologous Tissue Substitute J Synthetic Substitute K Nonautologous Tissue Substitute	H Transapical Z No Qualifier
F Aortic Valve			3 Percutaneous	8 Zooplastic Tissue	H Transapical N Rapid Deployment Technique Z No Qualifier

Replacement of Aortic Valve with Zooplastic Tissue, using Rapid Deployment Technique, Open

02RF08N Approach

Replacement of Aortic Valve with Zooplastic Tissue, using Rapid Deployment Technique,

02RF38N Percutaneous Approach

Replacement of Aortic Valve with Zooplastic Tissue, using Rapid Deployment Technique,

02RF48N Percutaneous Endoscopic Approach

Confidential • Do not distribute • ©Copyright Vitalware, LLC. All rights reserved.

5A0 – Extracorporeal or Systemic Assistance and Performance/ Physiological Systems/ Assistance

Section	5 8	Extracorporeal or Systemic Assista	nce and Performance			
Body System	A	Physiological Systems				
Operation	0 /	Assistance: Taking over a portion of	f a physiological function	n by extracorporeal means		
Body System		Duration	Function	Qualifier		
2 Cardiac		1 Intermittent	1 Output	 0 Balloon Pump 5 Pulsatile Compression 6 Other Pump D Impeller Pump 		
2 Cardiac		2 Continuous	1 Output	0 Balloon Pump5 Pulsatile Compression6 Other PumpD Impeller Pump		
2 Cardiac		2 Continuous	2 Oxygenation	C Supersaturated		
5 Circulatory		1 Intermittent 2 Continuous	2 Oxygenation	1 Hyperbaric		
9 Respiratory		2 Continuous	0 Filtration	Z No Qualifier		
9 Respiratory		3 Less than 24 Consecutive Hours 4 24-96 Consecutive Hours 5 Greater than 96 Consecutive Hours	5 Ventilation	7 Continuous Positive Airway Pressure 8 Intermittent Positive Airway Pressure 9 Continuous Negative Airway Pressure A High Nasal Flow/Velocity B Intermittent Negative Airway Pressure Z No Qualifier		

Code change eliminates the decision on intermittent versus continuous because it is always going to be continuous and now the code specifies cardiac rather than circulatory.

5A0222C Assistance with Cardiac Oxygenation, Supersaturated

BB3 - Imaging/ Respiratory System/ Magnetic Resonance Imaging (MRI)

Section	В	Imaging	Imaging			
Body System	В	Respiratory System				
Туре	3	Magnetic Resonance Imaging (MRI): Computer reformatted digital display of multiplanar images developed from the capture of radiofrequency signals emitted by nuclei in a body site excited within a magnetic field				
Body Part		Contrast	Qualifier	Qualifier		
4 Lungs, Bilateral		Z None	3 Hyperpolarized Xenon 129 (Xe-129)	Z None		
G Lung Apices		Y Other Contrast	0 Unenhanced and Enhanced Z None	Z None		
G Lung Apices		Z None	Z None	Z None		

BB34Z3Z Magnetic Resonance Imaging (MRI) of Bilateral Lungs using Hyperpolarized Xenon 129 (Xe-129)

XenoView Xe-129 MRI by Polarean

XXE- New Technology/ Physiological Systems/ Measurement

Section	X	New	Technology		
Body System	X	Phys	iological Systems		
Operation	E	Meas	surement: Determining the le	vel of a physiological or physical	function at a point in time
Body Part			Approach	Device / Substance / Technology	Qualifier
Central Nervous			X External	Intracranial Vascular Activity, Computer-aided Assessment	7 New Technology Group 7
Central Nervous			X External	4 Brain Electrical Activity, Computer-aided Semiologic Analysis	8 New Technology Group 8
3 Arterial			X External	2 Pulmonary Artery Flow, Computer-aided Triage and Notification	7 New Technology Group 7
3 Arterial			X External	5 Coronary Artery Flow, Quantitative Flow Ratio Analysis 6 Coronary Artery Flow, Computer-aided Valve Modeling and Notification	8 New Technology Group 8
5 Circulatory			X External	3 Infection, Whole Blood Reverse Transcription and Quantitative Real-time Polymerase Chain Reaction	8 New Technology Group 8
5 Circulatory			X External	M Infection, Whole Blood Nucleic Acid-base Microbial Detection	5 New Technology Group 5
5 Circulatory			X External	N Infection, Positive Blood Culture Fluorescence Hybridization for Organism Identification, Concentration and Susceptibility	6 New Technology Group 6
5 Circulatory			X External	R Infection, Mechanical Initial Specimen Diversion Technique Using Active Negative Pressure T Intracranial Arterial Flow, Whole Blood mRNA V Infection, Serum/Plasma Nanoparticle Fluorescence SARS-CoV-2 Antibody Detection	7 New Technology Group 7
9 Nose			7 Via Natural or Artificial Opening	U Infection, Nasopharyngeal Fluid SARS-CoV-2 Polymerase Chain Reaction	7 New Technology Group 7
B Respiratory			X External	Q Infection, Lower Respiratory Fluid Nucleic Acid-base Microbial Detection	6 New Technology Group 6

- Rapid sepsis detection
- Seizure analysis
- Coronary artery flow velocity
- Coronary artery obstruction risk for TAVR

 [©]Copyright Vitalware, LLC. All rights reserved.

XXE- New Technology/ Physiological Systems/ Measurement (continued)

Section	X	New Technology	New Technology		
Body System	X	Physiological Systems	Physiological Systems		
Operation	E	Measurement: Determining	the level of a physiological or physical	I function at a point in time	
Body Part		Approach	Device / Substance / Technology	Qualifier	
5 Circulatory		X External	3 Infection, Whole Blood Reverse Transcription and Quantitative Real-time Polymerase Chain Reaction	8 New Technology Group 8	

XXE5X38 Measurement of Infection, Whole Blood Reverse Transcription and q Quantitative Real-time Polymerase Chain Reaction, New Technology Group 8

Septi-Cyte RAPID

XXE- New Technology/ Physiological Systems/ Measurement (continued)

Section	X	New	New Technology			
Body System	X	Phys	Physiological Systems			
Operation	E	Meas	surement: Determining the le	evel of a physiological or physical	function at a point in time	
Body Part			Approach	Device / Substance / Technology	Qualifier	
0 Central Nervous			X External	4 Brain Electrical Activity, Computer-aided Semiologic Analysis	8 New Technology Group 8	

XXE0X48 Measurement of Brain Electrical Activity, Computer-aided Semiologic Analysis, New Technology Group 8


Nelli® Seizure Monitoring System

XXE - New Technology/ Physiological Systems/ Measurement (continued)

Section	Х	New Technology	New Technology			
Body System	X	Physiological Systems				
Operation	E	Measurement: Determining	Measurement: Determining the level of a physiological or physical function at a point in time			
Body Part		Approach	Device / Substance / Technology	Qualifier		
3 Arterial		X External	5 Coronary Artery Flow, Quantitative Flow Ratio Analysis	8 New Technology Group 8		
			Computer-aided Valve Modeling and Notification			

XXE3X58 Measurement of Coronary Artery Flow, Quantitative Flow Ratio Analysis, New Technology Group 8

Quantitative Flow Ratio (QFR®)



XXE - New Technology/ Physiological Systems/ Measurement (continued)

Section	X	New Technology		
Body System	X	Physiological Systems		
Operation	Ε	Measurement: Determining	the level of a physiological or physi	cal function at a point in time
Body Part		Approach	Device / Substance / Technology	Qualifier
3 Arterial		X External	5 Coronary Artery Flow, Quantitative Flow Ratio Analysis 6 Coronary Artery Flow, Computer-aided Valve Modeling and Notification	8 New Technology Group 8

XXE3X68 Measurement of Coronary Artery Flow, Computer-aided Valve Modeling and Notification, New Technology Group 8

Precision TAVI™ Valve Modeling

XW0- New Technology/ Anatomical Regions/ Introduction New Additions to the Device/Substance/Technology table:

Substance/Technology for FY2023
Afamitresgene Autoleucel Immunotherapy
Broad Consortium Microbiota-based Live Biotherapeutic Suspension
Daratumumab and Hyaluronidase-fihj
Engineered Allogeneic Thymus Tissue
Inebilizumab-cdon
Maribavir Anti-Infective
Mosunetuzumab Antineoplastic
Spesolimab Monoclonal Antibody
Tabelecleucel Immunotherapy
Teclistamab Antineoplastic
Treosulfan

XW0- New Technology/ Anatomical Regions/ Introduction

XW01318	Introduction of Daratumumab and Hyaluronidase-fihj into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8
XW01348	Introduction of Teclistamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8
XW020D8	Introduction of Engineered Allogeneic Thymus Tissue into Muscle, Open Approach, New Technology Group 8
XW03308	Introduction of Spesolimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 8
XW03358	Introduction of Mosunetuzumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 8 Introduction of Afamitresgene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology
XW03368	Group 8
XW03378	Introduction of Tabelecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8
XW03388	Introduction of Treosulfan into Peripheral Vein, Percutaneous Approach, New Technology Group 8
XW03398	Introduction of Inebilizumab-cdon into Peripheral Vein, Percutaneous Approach, New Technology Group 8
XW04308	Introduction of Spesolimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 8
XW04358	Introduction of Mosunetuzumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 8
	Introduction of Afamitresgene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology
XW04368	Group 8
XW04378	Introduction of Tabelecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8
XW04388	Introduction of Treosulfan into Central Vein, Percutaneous Approach, New Technology Group 8
XW04398	Introduction of Inebilizumab-cdon into Central Vein, Percutaneous Approach, New Technology Group 8
XW0DX38	Introduction of Maribavir Anti-infective into Mouth and Pharynx, External Approach, New Technology Group 8
XW0G738	Introduction of Maribavir Anti-infective into Upper GI, Via Natural or Artificial Opening, New Technology Group 8
XW0H738	Introduction of Maribavir Anti-infective into Lower GI, Via Natural or Artificial Opening, New Technology Group 8
	Introduction of Broad Consortium Microbiota-based Live Biotherapeutic Suspension into Lower GI, Via Natural or Artificial
XW0H7X8	Opening, New Technology Group 8

XW1- New Technology/ Anatomical Regions/ Transfusion

Section	X	New Technology		
Body System	W	Anatomical Regions		
Operation	1	Transfusion: Putting in blood	or blood products	
Body Part		Approach	Device / Substance / Technology	Qualifier
3 Peripheral Vein		3 Percutaneous	2 Plasma, Convalescent (Nonautologous)	5 New Technology Group 5
3 Peripheral Vein		3 Percutaneous	B Betibeglogene Autotemcel C Omidubicel	8 New Technology Group 8
3 Peripheral Vein		3 Percutaneous	D High-Dose Intravenous Immune Globulin E Hyperimmune Globulin	7 New Technology Group 7
3 Peripheral Vein		3 Percutaneous	F OTL-103 G OTL-200	8 New Technology Group 8
4 Central Vein		3 Percutaneous	2 Plasma, Convalescent (Nonautologous)	5 New Technology Group 5
4 Central Vein		3 Percutaneous	B Betibeglogene Autotemcel C Omidubicel	8 New Technology Group 8
4 Central Vein		3 Percutaneous	D High-Dose Intravenous Immune Globulin E Hyperimmune Globulin	7 New Technology Group 7
4 Central Vein		3 Percutaneous	F OTL-103 G OTL-200	8 New Technology Group 8

XW133B8	Transfusion of Betibeglogene Autotemcel into Peripheral Vein, Percutaneous Approach, New Technology Group 8
XW133C8	Transfusion of Omidubicel into Peripheral Vein, Percutaneous Approach, New Technology Group 8
XW133F8	Transfusion of OTL-103 into Peripheral Vein, Percutaneous Approach, New Technology Group 8
XW133G8	Transfusion of OTL-200 into Peripheral Vein, Percutaneous Approach, New Technology Group 8
XW143B8	Transfusion of Betibeglogene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 8
XW143C8	Transfusion of Omidubicel into Central Vein, Percutaneous Approach, New Technology Group 8
XW143F8	Transfusion of OTL-103 into Central Vein, Percutaneous Approach, New Technology Group 8
XW143G8	Transfusion of OTL-200 into Central Vein, Percutaneous Approach, New Technology Group 8

XY0- New Technology/ Extracorporeal/ Introduction

Section	X	New Technology		
Body System	Y	Extracorporeal		
Operation	0	Introduction: Putting in o substance except blood	r on a therapeutic, diagnostic, nutrition or blood products	al, physiological, or prophylactic
Body Part		Approach	Device / Substance / Technology	Qualifier
V Vein Graft		X External	8 Endothelial Damage Inhibitor	3 New Technology Group 3
Y Extracorporeal		X External	2 Taurolidine Anti-infective and Heparin Anticoagulan	
Y Extracorporeal		X External	3 Nafamostat Anticoagula	nt 7 New Technology Group 7

XY0YX28 Extracorporeal Introduction of Taurolidine Anti-infective and Heparin Anticoagulant, New Technology Group 8

DefenCath™

Deleted PCS Code	Deleted PCS Code Description	Potential Replacement Code(s)
5A0512C	Extracorporeal Supersaturated Oxygenation, Intermittent	5A0222C
5A0522C	Extracorporeal Supersaturated Oxygenation, Continuous	5A0222C
D0Y0KZZ	Laser Interstitial Thermal Therapy of Brain	00500Z3
D0Y0KZZ	Laser Interstitial Thermal Therapy of Brain	00503Z3
D0Y0KZZ	Laser Interstitial Thermal Therapy of Brain	00504Z3
D0Y1KZZ	Laser Interstitial Thermal Therapy of Brain Stem	00500Z3
D0Y1KZZ	Laser Interstitial Thermal Therapy of Brain Stem	00503Z3
D0Y1KZZ	Laser Interstitial Thermal Therapy of Brain Stem	00504Z3
D0Y6KZZ	Laser Interstitial Thermal Therapy of Spinal Cord	005W0Z3
D0Y6KZZ	Laser Interstitial Thermal Therapy of Spinal Cord	005W3Z3
D0Y6KZZ	Laser Interstitial Thermal Therapy of Spinal Cord	005W4Z3
D0Y6KZZ	Laser Interstitial Thermal Therapy of Spinal Cord	005X0Z3
D0Y6KZZ	Laser Interstitial Thermal Therapy of Spinal Cord	005X3Z3
D0Y6KZZ	Laser Interstitial Thermal Therapy of Spinal Cord	005X4Z3
D0Y6KZZ	Laser Interstitial Thermal Therapy of Spinal Cord	005Y0Z3
D0Y6KZZ	Laser Interstitial Thermal Therapy of Spinal Cord	005Y3Z3
D0Y6KZZ	Laser Interstitial Thermal Therapy of Spinal Cord	005Y4Z3
D0Y7KZZ	Laser Interstitial Thermal Therapy of Peripheral Nerve	NoPCS
DBY0KZZ	Laser Interstitial Thermal Therapy of Trachea	NoPCS
DBY1KZZ	Laser Interstitial Thermal Therapy of Bronchus	NoPCS
DBY2KZZ	Laser Interstitial Thermal Therapy of Lung	0B5K0Z3
DBY2KZZ	Laser Interstitial Thermal Therapy of Lung	0B5K3Z3
DBY2KZZ	Laser Interstitial Thermal Therapy of Lung	0B5K4Z3
DBY2KZZ	Laser Interstitial Thermal Therapy of Lung	0B5L0Z3

Deleted PCS Code	Deleted PCS Code Description	Potential Replacement Code
DBY2KZZ	Laser Interstitial Thermal Therapy of Lung	0B5L3Z3
DBY2KZZ	Laser Interstitial Thermal Therapy of Lung	0B5L4Z3
DBY2KZZ	Laser Interstitial Thermal Therapy of Lung	0B5M0Z3
DBY2KZZ	Laser Interstitial Thermal Therapy of Lung	0B5M3Z3
DBY2KZZ	Laser Interstitial Thermal Therapy of Lung	0B5M4Z3
DBY5KZZ	Laser Interstitial Thermal Therapy of Pleura	NoPCS
DBY6KZZ	Laser Interstitial Thermal Therapy of Mediastinum	NoPCS
DBY7KZZ	Laser Interstitial Thermal Therapy of Chest Wall	NoPCS
DBY8KZZ	Laser Interstitial Thermal Therapy of Diaphragm	NoPCS
DDY0KZZ	Laser Interstitial Thermal Therapy of Esophagus	0D550Z3
DDY0KZZ	Laser Interstitial Thermal Therapy of Esophagus	0D553Z3
DDY0KZZ	Laser Interstitial Thermal Therapy of Esophagus	0D554Z3
DDY1KZZ	Laser Interstitial Thermal Therapy of Stomach	0D560Z3
DDY1KZZ	Laser Interstitial Thermal Therapy of Stomach	0D563Z3
DDY1KZZ	Laser Interstitial Thermal Therapy of Stomach	0D564Z3
DDY2KZZ	Laser Interstitial Thermal Therapy of Duodenum	0D590Z3
DDY2KZZ	Laser Interstitial Thermal Therapy of Duodenum	0D593Z3
DDY2KZZ	Laser Interstitial Thermal Therapy of Duodenum	0D594Z3
DDY3KZZ	Laser Interstitial Thermal Therapy of Jejunum	0D5A0Z3
DDY3KZZ	Laser Interstitial Thermal Therapy of Jejunum	0D5A3Z3
DDY3KZZ	Laser Interstitial Thermal Therapy of Jejunum	0D5A4Z3
DDY4KZZ	Laser Interstitial Thermal Therapy of Ileum	0D5B0Z3
DDY4KZZ	Laser Interstitial Thermal Therapy of Ileum	0D5B3Z3
DDY4KZZ	Laser Interstitial Thermal Therapy of Ileum Confidential • Do not distribute • ©Copyright Vitalware II.C. All rights re	0D5B4Z3

Confidential • Do not distribute • @Copyright Vitalware, LLC. All rights reserved.

Deleted PCS Code	Deleted PCS Code Description	Potential Replacement Code
DDY5KZZ	Laser Interstitial Thermal Therapy of Colon	0D5E0Z3
DDY5KZZ	Laser Interstitial Thermal Therapy of Colon	0D5E3Z3
DDY5KZZ	Laser Interstitial Thermal Therapy of Colon	0D5E4Z3
DDY7KZZ	Laser Interstitial Thermal Therapy of Rectum	0D5P0Z3
DDY7KZZ	Laser Interstitial Thermal Therapy of Rectum	0D5P3Z3
DDY7KZZ	Laser Interstitial Thermal Therapy of Rectum	0D5P4Z3
DDY8KZZ	Laser Interstitial Thermal Therapy of Anus	0D5Q0Z3
DDY8KZZ	Laser Interstitial Thermal Therapy of Anus	0D5Q3Z3
DDY8KZZ	Laser Interstitial Thermal Therapy of Anus	0D5Q4Z3
DFY0KZZ	Laser Interstitial Thermal Therapy of Liver	0F500Z3
DFY0KZZ	Laser Interstitial Thermal Therapy of Liver	0F503Z3
DFY0KZZ	Laser Interstitial Thermal Therapy of Liver	0F504Z3
DFY1KZZ	Laser Interstitial Thermal Therapy of Gallbladder	0F540Z3
DFY1KZZ	Laser Interstitial Thermal Therapy of Gallbladder	0F543Z3
DFY1KZZ	Laser Interstitial Thermal Therapy of Gallbladder	0F544Z3
DFY2KZZ	Laser Interstitial Thermal Therapy of Bile Ducts	0F550Z3
DFY2KZZ	Laser Interstitial Thermal Therapy of Bile Ducts	0F553Z3
DFY2KZZ	Laser Interstitial Thermal Therapy of Bile Ducts	0F554Z3
DFY2KZZ	Laser Interstitial Thermal Therapy of Bile Ducts	0F560Z3
DFY2KZZ	Laser Interstitial Thermal Therapy of Bile Ducts	0F563Z3
DFY2KZZ	Laser Interstitial Thermal Therapy of Bile Ducts	0F564Z3
DFY2KZZ	Laser Interstitial Thermal Therapy of Bile Ducts	0F570Z3
DFY2KZZ	Laser Interstitial Thermal Therapy of Bile Ducts	0F573Z3
DFY2KZZ	Laser Interstitial Thermal Therapy of Bile Ducts	0F574Z3

Deleted PCS Code	Deleted PCS Code Description	Potential Replacement Code
DFY2KZZ	Laser Interstitial Thermal Therapy of Bile Ducts	0F580Z3
DFY2KZZ	Laser Interstitial Thermal Therapy of Bile Ducts	0F583Z3
DFY2KZZ	Laser Interstitial Thermal Therapy of Bile Ducts	0F584Z3
DFY2KZZ	Laser Interstitial Thermal Therapy of Bile Ducts	0F590Z3
DFY2KZZ	Laser Interstitial Thermal Therapy of Bile Ducts	0F593Z3
DFY2KZZ	Laser Interstitial Thermal Therapy of Bile Ducts	0F594Z3
DFY3KZZ	Laser Interstitial Thermal Therapy of Pancreas	0F5G0Z3
DFY3KZZ	Laser Interstitial Thermal Therapy of Pancreas	0F5G3Z3
DFY3KZZ	Laser Interstitial Thermal Therapy of Pancreas	0F5G4Z3
DGY0KZZ	Laser Interstitial Thermal Therapy of Pituitary Gland	0G500Z3
DGY0KZZ	Laser Interstitial Thermal Therapy of Pituitary Gland	0G503Z3
DGY0KZZ	Laser Interstitial Thermal Therapy of Pituitary Gland	0G504Z3
DGY1KZZ	Laser Interstitial Thermal Therapy of Pineal Body	0G510Z3
DGY1KZZ	Laser Interstitial Thermal Therapy of Pineal Body	0G513Z3
DGY1KZZ	Laser Interstitial Thermal Therapy of Pineal Body	0G514Z3
DGY2KZZ	Laser Interstitial Thermal Therapy of Adrenal Glands	0G520Z3
DGY2KZZ	Laser Interstitial Thermal Therapy of Adrenal Glands	0G523Z3
DGY2KZZ	Laser Interstitial Thermal Therapy of Adrenal Glands	0G524Z3
DGY2KZZ	Laser Interstitial Thermal Therapy of Adrenal Glands	0G530Z3
DGY2KZZ	Laser Interstitial Thermal Therapy of Adrenal Glands	0G533Z3
DGY2KZZ	Laser Interstitial Thermal Therapy of Adrenal Glands	0G534Z3
DGY2KZZ	Laser Interstitial Thermal Therapy of Adrenal Glands	0G540Z3
DGY2KZZ	Laser Interstitial Thermal Therapy of Adrenal Glands	0G543Z3
DGY2KZZ	Laser Interstitial Thermal Therapy of Adrenal Glands	0G544Z3

Deleted PCS Code	Deleted PCS Code Description	Potential Replacement Code
DGY4KZZ	Laser Interstitial Thermal Therapy of Parathyroid Glands	0G5R0Z3
DGY4KZZ	Laser Interstitial Thermal Therapy of Parathyroid Glands	0G5R3Z3
DGY4KZZ	Laser Interstitial Thermal Therapy of Parathyroid Glands	0G5R4Z3
DGY5KZZ	Laser Interstitial Thermal Therapy of Thyroid	0G5K0Z3
DGY5KZZ	Laser Interstitial Thermal Therapy of Thyroid	0G5K3Z3
DGY5KZZ	Laser Interstitial Thermal Therapy of Thyroid	0G5K4Z3
DMY0KZZ	Laser Interstitial Thermal Therapy of Left Breast	0H5U0Z3
DMY0KZZ	Laser Interstitial Thermal Therapy of Left Breast	0H5U3Z3
DMY1KZZ	Laser Interstitial Thermal Therapy of Right Breast	0H5T0Z3
DMY1KZZ	Laser Interstitial Thermal Therapy of Right Breast	0H5T3Z3
DVY0KZZ	Laser Interstitial Thermal Therapy of Prostate	0V500Z3
DVY0KZZ	Laser Interstitial Thermal Therapy of Prostate	0V503Z3
DVY0KZZ	Laser Interstitial Thermal Therapy of Prostate	0V504Z3
X2RF032	Replacement of Aortic Valve using Zooplastic Tissue, Rapid Deployment Technique, Open Approach, New Technology Group 2	02RF08N
X2RF332	Replacement of Aortic Valve using Zooplastic Tissue, Rapid Deployment Technique, Percutaneous Approach, New Technology Group 2	02RF38N
X2RF432	Replacement of Aortic Valve using Zooplastic Tissue, Rapid Deployment Technique, Percutaneous Endoscopic Approach, New Technology Group 2	02RF48N
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	0HR0XK3
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	0HR0XK4
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	0HR1XK3

Deleted PCS Code	Deleted PCS Code Description	Potential Replacement Code
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	OHR1XK4
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	OHR2XK3
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	0HR2XK4
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	OHR3XK3
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	OHR3XK4
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	OHR4XK3
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	OHR4XK4
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	OHR5XK3
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	OHR5XK4
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	OHR6XK3
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	OHR6XK4
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	OHR7XK3
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	0HR7XK4
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	0HR8XK3

Deleted PCS Code	Deleted PCS Code Description	Potential Replacement Code
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	OHR8XK4
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	OHR9XK3
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	OHR9XK4
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	0HRAXK3
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	0HRAXK4
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	OHRBXK3
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	OHRBXK4
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	0HRCXK3
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	0HRCXK4
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	0HRDXK3
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	0HRDXK4
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	OHREXK3
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	0HREXK4
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	OHRFXK3

Deleted PCS Code	Deleted PCS Code Description	Potential Replacement Code
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	OHRFXK4
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	0HRGXK3
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	0HRGXK4
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	OHRHXK3
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	0HRHXK4
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	0HRJXK3
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	0HRJXK4
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	OHRKXK3
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	OHRKXK4
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	0HRLXK3
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	0HRLXK4
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	0HRMXK3
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	0HRMXK4
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	OHRNXK3

Deleted PCS Code	Deleted PCS Code Description	Potential Replacement Code
XHRPXL2	Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2	OHRNXK4
XK02303	Introduction of Concentrated Bone Marrow Aspirate into Muscle, Percutaneous Approach, New Technology Group 3	3E023GC
XRG0092	Fusion of Occipital-cervical Joint using Nanotextured Surface Interbody Fusion Device, Open Approach, New Technology Group 2	0RG00A0
XRG0092	Fusion of Occipital-cervical Joint using Nanotextured Surface Interbody Fusion Device, Open Approach, New Technology Group 2	0RG00AJ
XRG00F3	Fusion of Occipital-cervical Joint using Radiolucent Porous Interbody Fusion Device, Open Approach, New Technology Group 3	0RG00A0
XRG00F3	Fusion of Occipital-cervical Joint using Radiolucent Porous Interbody Fusion Device, Open Approach, New Technology Group 3	0RG00AJ
XRG1092	Fusion of Cervical Vertebral Joint using Nanotextured Surface Interbody Fusion Device, Open Approach, New Technology Group 2	0RG10A0
XRG1092	Fusion of Cervical Vertebral Joint using Nanotextured Surface Interbody Fusion Device, Open Approach, New Technology Group 2	ORG10AJ
XRG10F3	Fusion of Cervical Vertebral Joint using Radiolucent Porous Interbody Fusion Device, Open Approach, New Technology Group 3	0RG10A0
XRG10F3	Fusion of Cervical Vertebral Joint using Radiolucent Porous Interbody Fusion Device, Open Approach, New Technology Group 3	ORG10AJ
XRG2092	Fusion of 2 or more Cervical Vertebral Joints using Nanotextured Surface Interbody Fusion Device, Open Approach, New Technology Group 2	0RG20A0
XRG2092	Fusion of 2 or more Cervical Vertebral Joints using Nanotextured Surface Interbody Fusion Device, Open Approach, New Technology Group 2	0RG20AJ
XRG20F3	Fusion of 2 or more Cervical Vertebral Joints using Radiolucent Porous Interbody Fusion Device, Open Approach, New Technology Group 3	0RG20A0
XRG20F3	Fusion of 2 or more Cervical Vertebral Joints using Radiolucent Porous Interbody Fusion Device, Open Approach, New Technology Group 3	0RG20AJ

Deleted PCS Code	Deleted PCS Code Description	Potential Replacement Code		
XRG4092	Fusion of Cervicothoracic Vertebral Joint using Nanotextured Surface Interbody Fusion Device, Open Approach, New Technology Group 2	0RG40A0		
XRG4092	Fusion of Cervicothoracic Vertebral Joint using Nanotextured Surface Interbody Fusion Device, Open Approach, New Technology Group 2	0RG40AJ		
XRG40F3	Fusion of Cervicothoracic Vertebral Joint using Radiolucent Porous Interbody Fusion Device, Open Approach, New Technology Group 3 ORG40A			
XRG40F3	Fusion of Cervicothoracic Vertebral Joint using Radiolucent Porous Interbody Fusion Device, Open Approach, New Technology Group 3			
XRG6092	Fusion of Thoracic Vertebral Joint using Nanotextured Surface Interbody Fusion Device, Open Approach, New Technology Group 2 ORG60A			
XRG6092	Fusion of Thoracic Vertebral Joint using Nanotextured Surface Interbody Fusion Device, Open Approach, New Technology Group 2 ORG60AJ			
XRG60F3	Fusion of Thoracic Vertebral Joint using Radiolucent Porous Interbody Fusion Device, Open Approach, New Technology Group 3	0RG60A0		
XRG60F3	Fusion of Thoracic Vertebral Joint using Radiolucent Porous Interbody Fusion Device, Open Approach, New Technology Group 3 ORG60			
XRG7092	Fusion of 2 to 7 Thoracic Vertebral Joints using Nanotextured Surface Interbody Fusion Device, Open Approach, New Technology Group 2	0RG70A0		
XRG7092	Fusion of 2 to 7 Thoracic Vertebral Joints using Nanotextured Surface Interbody Fusion Device, Open Approach, New Technology Group 2 ORG7			
Fusion of 2 to 7 Thoracic Vertebral Joints using Radiolucent Porous Interbody Fusion XRG70F3 Device, Open Approach, New Technology Group 3		0RG70A0		
Fusion of 2 to 7 Thoracic Vertebral Joints using Radiolucent Porous Inter XRG70F3 Device, Open Approach, New Technology Group 3		ORG70AJ		
XRG8092	Fusion of 8 or more Thoracic Vertebral Joints using Nanotextured Surface Interbody Fusion Device, Open Approach, New Technology Group 2	0RG80A0		
XRG8092	Fusion of 8 or more Thoracic Vertebral Joints using Nanotextured Surface Interbody Fusion Device, Open Approach, New Technology Group 2	0RG80AJ		

Deleted PCS Code	Deleted PCS Code Description	Potential Replacement Code		
XRG80F3	Fusion of 8 or more Thoracic Vertebral Joints using Radiolucent Porous Interbody Fusion Device, Open Approach, New Technology Group 3	0RG80A0		
XRG80F3	Fusion of 8 or more Thoracic Vertebral Joints using Radiolucent Porous Interbody Fusion Device, Open Approach, New Technology Group 3	ORG80AJ		
XRGA092	Fusion of Thoracolumbar Vertebral Joint using Nanotextured Surface Interbody Fusion Device, Open Approach, New Technology Group 2			
XRGA092	Fusion of Thoracolumbar Vertebral Joint using Nanotextured Surface Interbody Fusion Device, Open Approach, New Technology Group 2	0RGA0AJ		
XRGA0F3	Fusion of Thoracolumbar Vertebral Joint using Radiolucent Porous Interbody Fusion Device, Open Approach, New Technology Group 3	0RGA0A0		
XRGA0F3	Fusion of Thoracolumbar Vertebral Joint using Radiolucent Porous Interbody Fusion Device, Open Approach, New Technology Group 3	0RGA0AJ		
XRGB092	Fusion of Lumbar Vertebral Joint using Nanotextured Surface Interbody Fusion Device, Open Approach, New Technology Group 2	0SG00A0		
XRGB092	Fusion of Lumbar Vertebral Joint using Nanotextured Surface Interbody Fusion Device, Open Approach, New Technology Group 2 0SG0			
XRGB0F3	Fusion of Lumbar Vertebral Joint using Radiolucent Porous Interbody Fusion Device, Open Approach, New Technology Group 3	0SG00A0		
XRGB0F3	Fusion of Lumbar Vertebral Joint using Radiolucent Porous Interbody Fusion Device, Open Approach, New Technology Group 3	0SG00AJ		
Fusion of 2 or more Lumbar Vertebral Joints using Nanotextured Surface Interbo XRGC092 Fusion Device, Open Approach, New Technology Group 2		0SG10A0		
Fusion of 2 or more Lumbar Vertebral Joints using Nanotextured Surface Intel XRGC092 Fusion Device, Open Approach, New Technology Group 2		0SG10AJ		
XRGC0F3	Fusion of 2 or more Lumbar Vertebral Joints using Radiolucent Porous Interbody Fusion Device, Open Approach, New Technology Group 3	0SG10A0		
XRGC0F3	Fusion of 2 or more Lumbar Vertebral Joints using Radiolucent Porous Interbody Fusion Device, Open Approach, New Technology Group 3	0SG10AJ		

Deleted PCS Code	Deleted PCS Code Description	Potential Replacement Cod	
VDCD003	Fusion of Lumbosacral Joint using Nanotextured Surface Interbody Fusion Device,	0563040	
XRGD092	Open Approach, New Technology Group 2	0SG30A0	
	Fusion of Lumbosacral Joint using Nanotextured Surface Interbody Fusion Device,		
XRGD092	Open Approach, New Technology Group 2	0SG30AJ	
	Fusion of Lumbosacral Joint using Radiolucent Porous Interbody Fusion Device, Open		
XRGD0F3	Approach, New Technology Group 3	0SG30A0	
	Fusion of Lumbosacral Joint using Radiolucent Porous Interbody Fusion Device, Open		
XRGD0F3	Approach, New Technology Group 3	0SG30AJ	
	Introduction of Defibrotide Sodium Anticoagulant into Peripheral Vein, Percutaneous		
XW03392	Approach, New Technology Group 2	3E033GC	
	Introduction of Bezlotoxumab Monoclonal Antibody into Peripheral Vein,		
XW033A3	Percutaneous Approach, New Technology Group 3	3E033GR	
	Introduction of Defibrotide Sodium Anticoagulant into Central Vein, Percutaneous		
XW04392	Approach, New Technology Group 2	3E043GC	
	Introduction of Bezlotoxumab Monoclonal Antibody into Central Vein, Percutaneous		
XW043A3	Approach, New Technology Group 3	3E043GR	

PCS Guideline Changes

B3.19- Detachment

Detachment procedures of extremities

B3.19

The root operation Detachment contains qualifiers that can be used to specify the level where the extremity was amputated. These qualifiers are dependent on the body part value in the "upper extremities" and "lower extremities" body systems. For procedures involving the detachment of all or part of the upper or lower extremities, the procedure is coded to the body part value that describes the site of the detachment.

Example: An amputation at the proximal portion of the shaft of the tibia and fibula is coded to the Lower leg body part value in the body system Anatomical Regions, Lower Extremities, and the qualifier High is used to specify the level where the extremity was detached.

PCS Guideline Changes

The following definitions were developed for the Detachment qualifiers

Body Part	Qualifier	Definition
Upper arm and upper leg	1	High: Amputation at the proximal portion of the shaft of the humerus or femur
	2	Mid: Amputation at the middle portion of the shaft of the humerus or femur
	3	Low: Amputation at the distal portion of the shaft of the humerus or femur
Lower arm and lower leg	1	High: Amputation at the proximal portion of the shaft of the radius/ulna or tibia/fibula
	2	Mid: Amputation at the middle portion of the shaft of the radius/ulna or tibia/fibula
	3	Low: Amputation at the distal portion of the shaft of the radius/ulna or tibia/fibula
Hand and Foot	0	Complete*
	4	Complete 1st Ray
	5	Complete 2nd Ray
	6	Complete 3rd Ray
	7	Complete 4th Ray
	8	Complete 5th Ray
	9	Partial 1st Ray
	В	Partial 2nd Ray
	С	Partial 3rd Ray
	D	Partial 4th Ray
	F	Partial 5th Ray
Thumb, finger, or toe	0	Complete: Amputation at the metacarpophalangeal/metatarsal-phalangeal joint
	1	High: Amputation anywhere along the proximal phalanx
	2	Mid: Amputation through the proximal interphalangeal joint or anywhere along the middle phalanx
	3	Low: Amputation through the distal interphalangeal joint or anywhere along the distal phalanx

B3.19

The second part of Guideline B3.19 is a reference chart for the definitions used for each body part to be detached.

*When coding amputation of Hand and Foot, the following definitions are followed:

- Complete: Amputation through the carpometacarpal joint of the hand, or through the tarsal-metatarsal joint of the foot.
- Partial: Amputation anywhere along the shaft or head of the metacarpal bone of the hand, or of the metatarsal bone of the foot.

PCS Guideline Changes

B4.1c- Clarification

B4.1c

If a single vascular procedure is performed on a continuous section of an arterial or venous body part, code the body part value corresponding to the anatomically most proximal (closest to the heart) portion of the arterial or venous body part.

Example: A procedure performed on a continuous section of artery from the femoral artery to the external iliac artery with the point of entry at the femoral artery is coded to the external iliac body part. A procedure performed on a continuous section of artery from the femoral artery to the external iliac artery with the point of entry at the external iliac artery is also coded to the external iliac artery body part.

PCS Guideline Changes

B6.1a- Clarification on Complications

B6.1a

A device is coded only if a device remains after the procedure is completed. If no device remains, the device value No Device is coded. In limited root operations, the classification provides the qualifier values Temporary and Intraoperative, for specific procedures involving clinically significant devices, where the purpose of the device is to be utilized for a brief duration during the procedure or current inpatient stay. If a device that is intended to remain after the procedure is completed requires removal before the end of the operative episode in which it was inserted (for example, the device size is inadequate or an event documented as a complication occurs), both the insertion and removal of the device should be coded.

MS-DRG Changes

MS-DRG Changes

	TABLE 5.—LIST OF MEDICARE SEVERITY DIAGNOSIS-RELATED GROUPS (MS-DRGS), RELATIVE WEIGHTING FACTOR AND GEOMETRIC AND ARITHMETIC MEAN LENGTH OF STAY—FY 2023 Final Rule						
MS-DRG	FY 2023 Final Post-Acute DRG	FY 2023 Final Special Pay DRG	MDC	TYPE	MS-DRG Title	Weights	
021	No	No	01	SURG	INTRACRANIAL VASCULAR PROCEDURES WITH PRINCIPAL DIAGNOSIS	6.7892	
022	No	No	01	SURG	INTRACRANIAL VASCULAR PROCEDURES WITH PRINCIPAL DIAGNOSIS	4.3585	
023	Yes	Yes	01	SURG	CRANIOTOMY WITH MAJOR DEVICE IMPLANT OR ACUTE COMPLEX CN:	5.7314	
024	Yes	Yes	01	SURG	CRANIOTOMY WITH MAJOR DEVICE IMPLANT OR ACUTE COMPLEX CN:	3.9488	
025	Yes	No	01	SURG	CRANIOTOMY AND ENDOVASCULAR INTRACRANIAL PROCEDURES WIT	4.5405	
026	Yes	No	01	SURG	CRANIOTOMY AND ENDOVASCULAR INTRACRANIAL PROCEDURES WIT	3.0235	
027	Yes	No	01	SURG	CRANIOTOMY AND ENDOVASCULAR INTRACRANIAL PROCEDURES WIT	2.4954	
028	Yes	Yes	01	SURG	SPINAL PROCEDURES WITH MCC	5.8775	
029	Yes	Yes	01	SURG	SPINAL PROCEDURES WITH CC OR SPINAL NEUROSTIMULATORS	3.4176	
030	Yes	Yes	01	SURG	SPINAL PROCEDURES WITHOUT CC/MCC	2.3412	
031	Yes	No	01	SURG	VENTRICULAR SHUNT PROCEDURES WITH MCC	4.1210	
032	Yes	No	01	SURG	VENTRICULAR SHUNT PROCEDURES WITH CC	2.0545	
033	Yes	No	01	SURG	VENTRICULAR SHUNT PROCEDURES WITHOUT CC/MCC	1.6985	
034	No	No	01	SURG	CAROTID ARTERY STENT PROCEDURES WITH MCC	3.9994	
035	No	No	01	SURG	CAROTID ARTERY STENT PROCEDURES WITH CC	2.2838	
036	No	No	01	SURG	CAROTID ARTERY STENT PROCEDURES WITHOUT CC/MCC	1.8807	

-Identify top 20 MS-DRGs by volume at your facility

-Compare relative weights on those particular MS-DRGs between table 5 from FY 2022 and FY 2023.

-Useful information for finance, reimbursement, and revenue cycle leadership about upcoming potential case mix index and/or reimbursement changes.

https://www.cms.gov/medicare/acute-inpatient-pps/fy-2023-ipps-final-rule-home-page

Pre-MDC MS-DRG 018

Pre-MDC MS-DRG- 018 (Chimeric Antigen Receptor (CAR) T-Cell and Other Immunotherapies)

Classified the following new procedure codes as non-O.R. procedures affecting Pre-MDC MS-DRG 018

ICD-10-PCS Code	Description	XW043C7	Introduction of autologous engineered chimeric antigen receptor t-cell immunotherapy into central vein, percutaneous approach, new technology group 7 Introduction of allogeneic engineered chimeric antigen receptor t-cell	
XW033C7	Introduction of autologous engineered chimeric antigen receptor t-cell immunotherapy into peripheral vein, percutaneous approach, new technology	XW043G7		
XW033G7	Introduction of allogeneic engineered chimeric antigen receptor t-cell	XW043G7	immunotherapy into central vein, percutaneous approach, new technology group 7	
XW033H7	immunotherapy into peripheral vein, percutaneous approach, new technology group 7 Introduction of axicabtagene ciloleucel immunotherapy into peripheral vein,	XW043H7	Introduction of axicabtagene ciloleucel immunotherapy into central vein, percutaneous approach, new technology group 7	
XW033J7	percutaneous approach, new technology group 7 Introduction of tisagenlecleucel immunotherapy into peripheral vein,	XW043J7	Introduction of tisagenlecleucel immunotherapy into central vein, percutaneous approach, new technology group 7	
XW033K7	percutaneous approach, new technology group 7 Introduction of idecabtagene vicleucel immunotherapy into peripheral vein,	XW043K7	Introduction of idecabtagene vicleucel immunotherapy into central vein, percutaneous approach, new technology group 7	
XW033L7	percutaneous approach, new technology group 7 Introduction of lifileucel immunotherapy into peripheral vein, percutaneous approach, new technology group 7	XW043L7	Introduction of lifileucel immunotherapy into central vein, percutaneous approach, new technology group 7	
XW033M7	Introduction of brexucabtagene autoleucel immunotherapy into peripheral vein, percutaneous approach, new technology group 7	XW043M7	Introduction of brexucabtagene autoleucel immunotherapy into central vein, percutaneous approach, new technology group 7	
XW033N7	Introduction of lisocabtagene maraleucel immunotherapy into peripheral vein, percutaneous approach, new technology group 7	XW043N7	Introduction of lisocabtagene maraleucel immunotherapy into central vein, percutaneous approach, new technology group 7	

MDC 01 (Diseases & Disorders of the Nervous System)

Laser Interstitial Thermal Therapy (LITT) of brain and brain stem codes will now group to MS-DRGs 023, 024, 025, 026, 027 (Craniotomy and Endovascular procedures).

24 PCS codes describing insertion of a stimulator generator were added to MS-DRGs 252, 253, 254 (Other Vascular Procedures)

108 PCS code clusters describing the insertion of a stimulator generator (that is not differentiated by device type) and neurostimulator lead to MS-DRG 041 (Peripheral, cranial nerve and other nervous system procedures)

MDC 04 (Diseases and Disorders of the Respiratory System)

Cases reported to diagnosis code J80 (Acute respiratory distress syndrome) as principal diagnosis are being moved from MS-DRG 204 (Respiratory Signs and Symptoms) to MS-DRG 189 (Pulmonary Edema and Respiratory Failure).

MDC 05 (Diseases of the Cardiovascular System)

Procedure code 02UG3JE (Supplement mitral valve) moved from MS-DRG 231 and 232 (Coronary Bypass with PTCA) to MS-DRGs 266 and 267 (Endovascular Cardiac Valve Replacement and Supplement Procedures)

MDC 05 (Diseases and Disorders of the Circulatory System)

BAROSTIM NEO™ System procedures (0JH60MZ with 03HK3MZ or 03HL3MZ) reporting diagnosis code I97.130 or I97.131 (Postprocedural heart failure following cardiac/other surgery) as a principal diagnosis will now group to MS-DRGs 222 and 223 (Cardiac Defibrillator Implant with Cardiac Catheterization with AMI/HF/Shock)

PCS Code E02K80ZZ (Map conduction mechanism, open approach) moving from MS-DRGs 246-251 (Percutaneous Cardiovascular Procedures with Drug-Eluting Stent) to MS-DRGs 273 and 274 (Percutaneous and Other Intracardiac Procedures)

MDC 07 (Diseases of the Hepatobiliary System)

PCS code 0FC94ZZ (Extirpation of matter from common bile duct, percutaneous endoscopic approach) changed to an O.R. procedure and added to MS-DRGs 411, 412, 413 (Cholecystectomy with C.D.E)

MDC 15 (Newborns and Other Neonates)

Newborn encounter coded with a principal diagnosis code from category Z38 (Liveborn infants according to place of birth and type of delivery), followed by codes Z05.1 (Observation and evaluation of newborn for suspected infectious condition ruled out) and Z20.822 (Contact with and (suspected) exposure to COVID-19) moved from MS-DRG 794 (Neonate with Other Significant Problems) to MS-DRG 795 (Normal Newborn).

13 other contact and suspected exposure codes (Z20.01-Z20.9) were moved to MS-DRG 795 (Normal Newborn).

Codes P07.0 (Extremely low birth weight newborn, unsp weight), P07.20 (Extreme immaturity of newborn, unsp weight), and P07.26 (Extreme immature newborn gest age 27 weeks) moved to MS-DRG 790 (Extreme Immaturity or Respiratory Distress Syndrome Neonate).

Operating Room (O.R.) and Non-O.R. Issues

Procedure codes for embolization of portal or hepatic veins (06L43DZ, 06L83DZ, 06V43DZ, 06V83DZ moved from MS-DRGS 981-983 (Extensive O.R. Procedure unrelated to Principal Dx) and now assign to MS-DRGs 423, 424, and 425 (Other Hepatobiliary or Pancreas Procedures).

Excision of hip muscle (biopsy) codes 0KBN3ZX, 0KBN3ZZ, 0KBP3ZX, 0KBP3ZZ with a PDX such as K68.12, psoas abscess moved from MS-DRGS 981-983 (Ext. O.R. Procedure) to 371, 372, and 373 (Major Gastrointestinal Disorders and Peritoneal Infections.) No longer O.R. procedures!

Vitalware® by Health Catalyst®

A single, connected solution for managing your hospital's revenue integrity.

Core Solutions

VitalKnowledge®

Regulatory and Coding Content

VitalCDM®

Chargemaster Management

VitalIntegrity[™] | VitalAnalysis

Charge Capture

Hospital Price Index (HPI)

Price Transparency Compliance

#1 in KLAS Revenue Cycle, Chargemaster Management Four Years in a Row



Resources

Libman Education Medical Coding and Training eLearning: ICD-10-CM and ICD-10-PCS Fiscal Year 2023 Updates https://libmaneducation.com/

Centers for Medicare and Medicaid Services (CMS). ICD-10-CM 2023. https://www.cms.gov/medicare/icd-10/2023-icd-10-cm

Centers for Medicare and Medicaid Services (CMS). ICD-10-PCS 2023. https://www.cms.gov/medicare/icd-10/2023-icd-10-pcs

Centers for Medicare and Medicaid Services (CMS). Inpatient Prospective Payment System (IPPS) Final Rule 2023.

https://www.cms.gov/medicare/acute-inpatient-pps/fy-2023-ipps-final-rule-home-page

Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2023 Rates; Quality Programs and Medicare Promoting Interoperability Program Requirements for Eligible Hospitals and Critical Access Hospitals; Costs Incurred for Qualified and Non-Qualified Deferred Compensation Plans; and Changes to Hospital and Critical Access Hospital Conditions of Participation.

https://www.federalregister.gov/documents/2022/08/10/2022-16472/medicare-program-hospital-inpatient-prospective-payment-systems-for-acute-care-hospitals-and-the

Part 3: New ICD-10 Codes and IPPS Changes for 2023. https://hiacode.com/blog/icd10-ipps-changes-2023

Thank you!

Questions?